Document:

EX-10.8

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 Exhibit 10.8 

Patent Sublicense Agreement 

This Patent Sublicense Agreement (“Agreement”) is between CELLSCRIPT, LLC, a Wisconsin limited liability company having a
place of business at 726 Post Road, Madison, WI 53713, USA (“Cellscript”) and ModernaTx, Inc., a Delaware corporation having a place of business at 320 Bent Street, Cambridge, MA 02141, USA (“Company”). This
Agreement is effective as of June 26, 2017 (the “Effective Date”). Each of Company and Cellscript are referred to herein as a “Party” and collectively as the “Parties”. 

BACKGROUND 
 WHEREAS, mRNA
RiboTherapeutics, Inc. (“mRNA RiboTherapeutics”) has an exclusive license from the Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”) for certain intellectual property
comprising patents, patent applications and technology relating to use of modified ribonucleic acid (RNA) technology which was developed by Drs. Drew Weissman and Katalin Kariko of Penn’s Perelman School of Medicine as described in [***], and
certain other intellectual property comprising patents, patent applications and technology relating to the modified RNA technology, inter alia, for reprogramming of mammalian cells to induced pluripotent stem cells, as described in [***], pursuant
to the Second Amended and Restated Patent License Agreement which became effective as of December 20, 2016 (the “Penn License Agreement”), under which Cellscript has a sublicense from mRNA RiboTherapeutics in certain fields of
use pursuant to the Amended and Restated Patent Sublicense Agreement which became effective as of December 20, 2016 (the “Cellscript Sublicense Agreement”), under which Cellscript has the right to further sublicense all or any
part of the rights granted to Cellscript to other parties; and 
 WHEREAS, Company desires a sublicense to the Patents Rights (as defined
below) from Cellscript for in vivo uses in humans and non-human animals and for certain other uses pertaining thereto and Cellscript is willing to grant to Company a sublicense to said intellectual
property for such uses under the terms and conditions herein; 
 NOW, THEREFORE, in consideration of the mutual obligations contained in
this Agreement, and intending to be legally bound, the Parties agree as follows: 
 1     SUBLICENSE 

1.1    Sublicense Grant. Cellscript hereby grants to Company and Company hereby accepts from Cellscript a worldwide,
non-exclusive sublicense under the Patent Rights during the Term to make, have made, import, use, offer for sale, sell and/or have sold Licensed Products according to the terms and conditions herein:
(1) in Field of Use B for all uses in the In Vivo Field of Use, including: (a) all therapeutic and prophylactic uses in humans; (b) all non-therapeutic and
non-prophylactic uses in humans; and (c) all uses, including therapeutic and prophylactic uses (e.g., Veterinary Products), in non-human animals; and (2) in
Field of Use A for internal research and screening uses, including [***], including for the Fields of Use in (1)(a) through (1)(c); ((1) and (2) collectively, the “Sublicensed Fields of Use”), as all said terms are defined in
Sections 1.2 and 6.1 herein (the “Sublicense”). The Sublicense includes the right for Company to grant sublicenses to its affiliates and Third Parties for all or any part of the rights and fields of use granted to Company, under
terms that are consistent with this Agreement. No other rights or licenses are granted by Cellscript to Company under this Agreement; [***]. 

  
 1 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 1.2    Related Definitions. 

Whenever the words or terms “comprising,” “containing,” “having,” “include,” includes,”
“including,” “such as,” “for example,” “an example,” “examples,” “e.g.,” “for further clarification” or the like are used in this Agreement, they shall be understood to be
followed by the words “without limitation” or “but without limitation”. The terms “a,” “an,” and “the” and the use of such terms or nouns in definitions in either the singular or the plural are to be
construed to cover both the singular and the plural unless otherwise noted. 
 “Licensed Products” means products that are
made, made for, used, imported, offered for sale or sold by Company or its Affiliates or Third Party sublicensees [***]. For clarity, Licensed Products includes any method, procedure or process, the use of which by Company or its Affiliates or Third
Party sublicensees, [***]. 
 “Exhibit A-1 Patent Rights” means all of Penn’s
patent rights represented by or issuing from: (a) the United States and PCT patents and patent applications listed in Exhibit A-1; (b) any continuation, divisional, reexamination, and re-issue applications of (a); and (c) any extensions and foreign counterparts of (a) or (b). 

“Exhibit A-2 Patent Rights” means all of Penn’s patent rights represented by or
issuing from: (a) the United States and PCT patents and patent applications listed in Exhibit A-2; (b) any continuation, divisional, reexamination, and re-issue
applications of (a); and (c) any extensions and foreign counterparts of (a) or (b). 
 “Patent Rights” means
Exhibit A-1 Patent Rights and/or Exhibit A-2 Patent Rights. 

“Affiliate” means a legal entity that is controlling, controlled by or under common control with Company and that has
executed either this Agreement, a sublicense for at least a portion of the rights granted to Company under this Agreement, or a written joinder agreement agreeing to be bound by all of the terms and conditions of this Agreement. The uncapitalized
term “affiliate” means, with respect to a first legal entity, any other legal entity that is controlling, controlled by or under common control with said first legal entity. For purposes of the definitions of “Affiliate”
and “affiliate” herein, the word “control” means (x) the direct or indirect ownership of fifty percent (50%) or more of the outstanding voting securities of a legal entity, (y) the right to receive fifty percent
(50%) or more of the profits or earnings of a legal entity, or (z) the right to determine the policy decisions of a legal entity. 

“Field of Use A” means and is limited to internal laboratory research or screening [***]. For clarity, Field of Use A
includes [***]. For further clarity, a party that has a sublicense in Field of Use A pertaining to a sublicensed therapeutic or prophylactic or diagnostic or prognostic use in Field of Use B shall have the right to [***]. 

[***] 
 “Field of Use
B” means the field other than Field of Use A and includes but is not limited to therapeutic, prophylactic, diagnostic, prognostic and cosmetic uses in humans and agricultural, animal improvement and veterinary uses in animals. For clarity,
Field of Use B includes any and all fields of use, including the In Vivo Field of Use and Ex Vivo Field of Use, other than for Field of Use A. 

“Fields of Use” means Field of Use A and Field of Use B. 

“Ex Vivo Field of Use” is a subfield of Field of Use A or Field of Use B wherein a product or method that is
covered by Patent Rights is used in cells, tissues or organs that are ex vivo or outside of a living human or animal body or organism, [***]. 

  
 2 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 “In Vivo Field of Use” is a subfield of Field of Use A or
Field of Use B wherein a product or method that is covered by Patent Rights is used in vivo, [***]. 
 “Diagnostic and
Prognostic Field of Use” is a subfield of use within Field of Use B wherein a product or service covered by Patent Rights is used for diagnosis, prognosis or testing of a human or non-human animal or
a sample therefrom in order to detect, identify, determine a cause, evaluate, analyze, understand, predict, rule in, or rule out a medical condition or disease or to predict an effect or response to treatment, and/or to monitor the effect of a
treatment of such medical condition or disease. [***] 
 “Veterinary Product” means a product that is covered by Patent
Rights which is used for the care, treatment, breeding or use of livestock or companion animals. 
 “Third Party” means any
person, corporation, partnership, association, consortium or business, legal or governmental entity other than Penn, Cellscript, Company or any of their respective affiliates. 

[***] 

1.3    Reservation of Rights by Penn. Penn reserves the right to use, and to permit other non-commercial entities to use, the Patent Rights for educational and non-commercial research purposes. 

1.4    U.S. Government Rights. The Parties acknowledge that the United States government retains rights in
intellectual property funded under any grant or similar contract with a Federal agency. The License is expressly subject to all applicable United States government rights, including, but not limited to, any applicable requirement that products,
which result from such intellectual property and are sold in the United States, must be substantially manufactured in the United States. 

1.5    Sublicense Conditions. Company’s right to extend any or all of the rights granted to Company by
Cellscript via a sublicense to affiliates or Third Parties is subject to each of the following conditions:  

1.5.1    Company will have the right to grant further sublicenses to its affiliates and to Third Parties (“sub-sublicensees”) that permit multiple levels of sublicensing, including in Third Party sub-sublicenses that permit further levels of sublicensing (e.g., to “sub-sub-sublicensees”). In each further sub-sublicense agreement to an affiliate or Third Party, Company will require the sub-sublicensee to comply with terms and conditions that are consistent with this Agreement, and in each agreement for further sublicensing (e.g., by a sub-sublicensee of
Company to a sub-sub-sublicensee), the party granting the further sublicense will require the party receiving the further sublicense to comply with terms and conditions
that are consistent with its sub-sublicense agreement from Company. Except when used to clarify the meaning of the different terms in this Section 1.5.1, the term sublicense in this Agreement includes any
permitted sub-sublicense, sub-sub-sublicense, etc. and the term sublicensee includes any permitted sub-sublicensee, sub-sub-sublicensee, etc. 
 1.5.2    Within
[***] days after Company enters into a sublicense agreement, Company will deliver to Cellscript a complete and accurate copy of the entire sublicense agreement written in the English language, provided that Company will have the right to redact the
terms and conditions of such sublicense agreement that are not necessary for Cellscript to confirm compliance with all terms and conditions required under this Sublicense, including Section 1.5 hereof. Cellscript’s receipt of the
sublicense agreement will not constitute a waiver of any right or obligation of Cellscript or of Company under this Agreement. 

  
 3 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 1.5.3    In the event that Company causes or experiences a Trigger Event
(as defined in Section 6.4), to the extent permissible by law, [***]. 
 1.5.4    Company’s execution of a
sublicense agreement will not relieve Company of any of its obligations under this Agreement. Company is primarily liable to Cellscript for any act or omission of a sublicensee that would be a breach of this Agreement if performed or omitted by
Company, and Company will be deemed to be in breach of this Agreement as a result of such act or omission. Upon learning of any such breach of this Agreement due to an act or omission of a sublicensee of Company, Company will [***]. Provided that
Company [***], a breach by said sublicensee shall not be considered a breach by Company that will be considered a cause for termination of this Agreement under Section 6.3. 

1.5.5    A sublicense granted by the Company or a further sublicensee thereof will not be assignable or transferable by
said sublicensee or further sublicensee thereof without the prior written consent of Cellscript, except to an affiliate of the sublicensee of Company or an affiliate of said further sublicensee thereof, or to a Third Party company that: (i) can
demonstrate based on reliable financial information that it has all technical knowledge, capabilities and/or financial resources needed to perform in all respects in the place and stead of said sublicensee or further sublicensee thereof;
(ii) agrees to assume all duties and responsibilities under the sublicense; [***]; and (v) agrees in writing to be bound by all of the terms and conditions of the sublicense and a copy of such written undertaking is promptly provided to
Company, which will provide a copy to Cellscript, which, in turn, will provide a copy to mRNA RiboTherapeutics. 

1.6    No License by Implication. Nothing in this Agreement confers by estoppel implication or otherwise, any
license or rights under any Penn patent other than rights granted under patents included in the Patent Rights and Exhibit D Patents, regardless whether such patents are dominant or subordinate to the Patent Rights and Exhibit D Patents. 

1.7    License to the Exhibit D Patents. Whereas Cellscript has an exclusive license from Penn for certain U.S.
patents and patent applications listed in Exhibit D hereto, including any continuation, divisional, reexamination, and re-issue applications and any patents or extensions of any of the foregoing (collectively
referred to as “Exhibit D Patents” herein), which Exhibit D Patents are not included in Patent Rights herein; and whereas, Company desires a sublicense to Exhibit D Patents in the Sublicensed Fields of Use during the Term and
Cellscript is willing to grant such a sublicense in the Sublicensed Fields of Use according to the terms and conditions herein, now, therefore, Cellscript hereby grants to Company and Company hereby accepts from Cellscript a limited worldwide, non-exclusive sublicense under Exhibit D Patents during the Term to make, have made, import, use, offer for sale, sell and/or have sold Licensed Products which are also covered by Exhibit D Patents, solely in the
Sublicensed Fields of Use, and according to the terms and conditions herein. The sublicense includes the right for Company to grant sublicenses to its affiliates and Third Parties for all or any part of the rights granted to Company in the
Sublicensed Fields of Use, under terms that are consistent with this Agreement. No other rights or licenses pertaining to Exhibit D Patents are granted by Cellscript to Company under this Agreement. [***] 

1.8    Relation of this Agreement to mRNA RiboTherapeutics Sublicense Agreement. Concurrent with the execution of this Agreement,
Company is entering into a separate sublicense agreement with mRNA RiboTherapeutics (the “mRNA RiboTherapeutics Sublicense Agreement”), pursuant to which mRNA RiboTherapeutics is granting Company a sublicense under Patent Rights
with respect to certain fields of use that are different from and are not included within the scope of the Sublicense granted to Company in this Agreement 

  
 4 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 2    DILIGENCE 

2.1    Development Plan and Sublicense Disclosure Report. By [***], Company will deliver to Cellscript: (1) a
copy of an annual development plan, including [***] and a summary of material development efforts for Licensed Products since the last development plan (“Development Plan”); [***] (2) a Sublicense Disclosure Report
(“SDR”), [***]. 
 2.2    Company’s Efforts. Company will use commercially reasonable
efforts to develop, commercialize, market and sell Licensed Products in the Sublicensed Fields of Use in a manner consistent with the Development Plan. In addition to Company’s own efforts to develop, commercialize, market and sell Licensed
Products, the efforts of other parties, including Affiliates, Third Party sublicensees, contractors, Third Parties funded by Company under a research or service agreement, and distributors, will also be deemed as efforts of Company. 

2.3    Diligence Events. Company, whether itself, or through its Affiliates, Third Party sublicensees, contractors,
or Third Parties funded by Company under a research or service agreement, will use commercially reasonable efforts to achieve each of the milestone diligence events by the applicable completion date listed in the table below for the first Licensed
Product for human therapeutic or prophylactic use in Field of Use B. Company will provide Cellscript with written notice within [***] days of first completion of each milestone diligence event for a Licensed Product for human therapeutic or
prophylactic use in Field of Use B by Company or an Affiliate or Third Party sublicensee. 
  

			
	 MILESTONE DILIGENCE EVENT
	  	COMPLETION
DATE
	 1. [***]
	  	[***]
	 2. [***]
	  	[***]
	 3. [***]
	  	[***]
	 4. [***]
	  	[***]
	 5. [***]
	  	[***]

 2.4    Diligence Resources. Until [***], Company will expend financial resources
for the development and commercialization of the Licensed Products in amounts not less than the diligence minimums specified in the table below (“Development Expenditures”) in each [***] period following the Effective Date.
Development Expenditures shall include all research and development expenditures directly relating to Licensed Products, including [***]. If Company’s total expenditures for development and commercialization of Licensed Products in any [***] do
not meet or exceed the applicable diligence minimum, then [***]. 
  

							
	 ANNIVERSARY:
	  	[***]	  	[***]	  	[***]
	 SUBLICENSE DILIGENCE FEE:
	  	[***]	  	[***]	  	[***]

  
 5 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 3    FEES AND ROYALTIES 

3.1    Sublicense Grant Fees. In partial consideration for the Sublicense, Company will pay to Cellscript: [***] a
non-refundable, non-creditable sublicense fee of twenty-two million U.S. dollars ($22,000,000) on [***] of 2019, [***]. 

3.2    Sublicense Maintenance Fees. In partial consideration of the Sublicense, Company will pay to Cellscript
[***] on each [***] occurring during the Term until the date of [***]. For clarity, the next annual sublicense maintenance fee under this Agreement is payable to Cellscript on [***]. 

3.3    Milestone Payments. In partial consideration of the Sublicense, promptly following the Effective Date,
Company will provide Cellscript with [***] and Company will pay to Cellscript within [***] after the Effective Date all [***]. Thereafter, in further partial consideration of the Sublicense, Company will pay to Cellscript the milestone payment
listed in Table A or Table C in this Section 3.3, as applicable, [***], regardless of whether the milestone is achieved by Company, an Affiliate or a Third Party sublicensee. Company will provide Cellscript with written notice within [***] days
after each milestone is achieved by Company or a sublicensee and Company will pay to Cellscript all applicable milestone payments owed therefor within [***] days of the end of the calendar quarter in which the milestone event is achieved. [***] 

[Remainder of Page Intentionally Left Blank] 

  
 6 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

			
	 Section 3.3 Table A

MILESTONES for [***] [***]

	 MILESTONE EVENT
	  	Payment
to Cellscript
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 TOTAL
	  	$25,500,000

  

			
	 Section 3.3 Table C

MILESTONES for [***]

	 MILESTONE EVENT
	  	Payment
to Cellscript
	 [***]
	  	[***]
	 [***]
	  	[***]

 3.4    Earned Royalties. In partial consideration of the Sublicense, Company will
pay to Cellscript royalties on Net Sales of Licensed Products in the Sublicensed Fields of Use as stated below. 

3.4.1    Earned Royalties on Licensed Products in Field of Use A. In partial consideration of the Sublicense,
Company will pay to Cellscript a [***] percent ([***]%) royalty on Net Sales of Licensed Products by Company or its Affiliates or Third Party sublicensees for use in [***] during the Quarter. For the avoidance of doubt, if Company or any Affiliate
or Third Party sublicensee [***], then Company will pay to Cellscript [***] on all such Net Sales of Licensed Products for use in Field of Use A by Company or by said sublicensees. For clarity, Company and its Affiliates or Third Party sublicensees
shall not [***]. 
 3.4.2    Earned Royalties on Licensed Products for the In Vivo Field of Use
in Field of Use B. In partial consideration of the Sublicense, Company will pay to Cellscript a [***] percent ([***]%) royalty on Net Sales of Licensed Products in Field of Use B for all uses in the In Vivo Field of Use, including: [***]
during the Quarter. For the avoidance of doubt, if Company or its Affiliates or Third Party sublicensees grant sublicenses to sell Licensed Products for any such uses in Field of Use B, Company will pay to Cellscript a [***] percent [***] royalty on
Net Sales of all such Licensed Products sold by said sublicensees. 

  
 7 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 3.4.3    Royalty Reduction. If Company or an Affiliate or Third
Party sublicensee of Company is obligated to pay [***] (defined below) for a Licensed Product [***], then Company may deduct [***] percent ([***]%) of such [***] from any royalties on Net Sales in [***] due to Cellscript under Section 3.4.2 of
this Agreement, provided that: 
 (a)    On an ongoing basis and prior to reduction of any royalty on
Net Sales for a given calendar quarter, Company first provides [***]; and 
 (b)    In no event shall
royalties on Net Sales due to Cellscript in any reporting period be so reduced to less than [***] percent ([***]%) for Licensed Products for use in the In Vivo Field of Use in Field of Use B. 

“[***]” means any [***] that Company or an Affiliate or a Third Party sublicensee owes to one or more other parties pursuant to one
or more licenses for [***] that are determined to be [***] with respect to the manufacture, use or sale of any Licensed Product. 

3.5    Related Definitions. 

3.5.1    The term “Sale” means any bona fide transaction for which consideration is received or expected
by Company or its Affiliates or Third Party sublicensees for the sale, use, lease, transfer or other disposition of a Licensed Product to a Third Party. A Sale is deemed completed at the time that Company or an Affiliate or Third Party [***]. 

3.5.2    The term “Quarter” means each three-month period beginning on the first day of January, April,
July or October. 
 3.5.3    The term “Net Sales” means the consideration [***]. 

  
 8 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 3.5.4    The term “Qualifying Costs” means: [***]. 

3.6    Minimum Royalties. In partial consideration of the Sublicense, and only to the extent that [***], Company
will pay to Cellscript the amount, if any, by which the applicable minimum royalties listed for the respective Categories in the tables below exceed Company’s or its Affiliates’ or Third Party sublicensees’ actual earned royalties
under Section 3.4 for each Quarter after the first Sale of a Licensed Product in the Sublicensed Fields of Use in each said Category by Company or its Affiliates or Third Party sublicensees. For sake of clarity, the highest minimum royalty owed
by Company to Cellscript under this Agreement would be [***]. 
 Category 1 - Licensed Products in Field of Use A 

 

					
	 QUARTER:
	  	[***]	  	[***]
	 MINIMUM:
	  	[***]	  	[***]

 Category 2 - Licensed Products in Field of Use B 

For [***][***] 
  

					
	 QUARTER:
	  	[***]	  	[***]
	 MINIMUM:
	  	[***]	  	[***]

 Category 3 - Licensed Products in Field of Use B 

That [***] 
 For [***][***] 

 

					
	 QUARTER:
	  	[***]	  	[***]
	 MINIMUM:
	  	[***]	  	[***]

  
 9 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 4    REPORTS AND PAYMENTS 

4.1    Royalty Reports. Within [***] days after the end of each Quarter following the first Sale, Company will
deliver to Cellscript a report, [***], detailing the calculation of all royalties, fees and other payments due to Cellscript for such Quarter. The report will include, at a minimum, the following information for the Quarter, each listed by product,
by country: [***]. 
 4.2    Payments. Company will pay all royalties, fees and other payments due to Cellscript
under Sections 3.3, 3.4 and 3.6 within [***] days after the end of the Quarter in which the royalties, fees or other payments accrued. Cellscript agrees that it will pay all such amounts to mRNA RiboTherapeutics according to and within the time
periods required by the Cellscript Sublicense Agreement, and mRNA RiboTherapeutics will pay to Penn all royalties, fees and other payments due to Penn according to and within the time periods required by the Penn License Agreement. For clarity,
(a) only one royalty will be due with respect to the Sale of the same unit of Licensed Product and (b) royalties are payable hereunder only on Sales of Licensed Product for use in the Sublicensed Fields of Use, it being understood that
Company and its sublicensees have no right to sell Licensed Products in any Fields of Use except Sublicensed Fields of Use. 

4.3    Records. Company will maintain, and will cause its Affiliates and Third Party sublicensees to maintain,
complete and accurate books, records and related background information to verify Sales, Net Sales, and all of the royalties, fees, and other payments due or paid under this Agreement, as well as the various computations reported under
Section 4.1. The records for each Quarter will be maintained for at least [***] years after submission of the applicable report required for Section 4.1. 

4.4    Audit Rights. Upon [***], Company and its Affiliates and Third Party sublicensees will provide Penn and its
accountants (or Cellscript and its accountants in the event that Cellscript is Penn’s designated auditor) with access to [***] to conduct a review or audit of Sales, Net Sales, and all of the royalties, fees, and other payments payable under
this Agreement. Access will be made available: (a) during normal business hours; (b) in a manner reasonably designed to facilitate such accountant’s review or audit without unreasonable disruption to Company’s business; and
(c) no more than [***] during the Term (as defined below) and for a period of [***] thereafter. Company will promptly pay to Cellscript the amount of any underpayment determined by the review or audit, plus accrued interest. If the review or
audit determines that Company has underpaid any payment by [***] percent ([***]%) or more, then Company will also promptly pay the costs and expenses of the auditing party’s accountants in connection with the review or
audit.    In addition, once annual Sales of Licensed Products exceed [***]. 

4.5    Currency. All dollar amounts referred to in this Agreement are expressed in United States dollars. All
payments will be made in United States dollars. If Company receives payment from a sublicensee in a currency other than United States dollars for which a royalty or fee is owed under this Agreement, then (a) the payment will be converted into
United States dollars at the conversion rate for the foreign currency as published in the eastern edition of the Wall Street Journal as of the last business day of the Quarter in which the payment was received by Company, and (b) the conversion
computation will be documented by Company in the applicable report delivered to Cellscript under Section 4.1. 

  
 10 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 4.6    Place of Payment. All payments by Company to CELLSCRIPT,
LLC and will be made to the following addresses: 
  

			
	 By ACH/Wire:
	  	 By Check (direct mail):

	 [***]
	  	 [***]

	 [***]
	  	 [***]

	 [***]
	  	
	 [***]
	  	 [***]

 4.7    Interest. All amounts that are not paid by Company when due will accrue
interest from the date due until paid at a rate equal to [***] percent ([***]%) per month (or the maximum allowed by law, if less). 

5    CONFIDENTIALITY AND USE OF NAMES 

5.1    Confidentiality. Each Party agrees that it will not, under this Agreement, provide to the other Party
or its affiliates any Confidential Information of such Party unless (i) such Party has first identified the general nature of such Confidential Information to such other Party in writing and such other Party has affirmatively agreed in writing
to receive such Confidential Information, or (ii) such other Party has specifically requested such Confidential Information in writing. For clarity, any such consent or request issued by email or other written electronic means shall satisfy the
foregoing “writing” requirements. Any Confidential Information disclosed by a Party to the other Party other than in accordance with this Section 5.1 will be deemed not to be Confidential Information of such Party. Notwithstanding the
foregoing, Cellscript is obligated to accept and treat as confidential any Confidential Information disclosed by Company in the reports or notices required by Sections 2.1, 2.3, 3.3, 3.4.3(a), 4.1, 4.4, 4.6 and 6.6, which information Company
agrees Cellscript may disclose to mRNA RiboTherapeutics or Penn without the prior written consent of Company. 

5.2    Confidential Information. Each Party (“Disclosing Party”) may disclose to the other Party
(“Receiving Party”), and Receiving Party may acquire during the course and conduct of activities under the Agreement, certain proprietary or confidential information of Disclosing Party in connection with this Agreement. The term
“Confidential Information” shall mean all ideas and information of any kind, whether in written, oral, graphical, machine-readable or other form, whether or not marked as confidential or proprietary, which are transferred, disclosed
or made available by Disclosing Party in accordance with Section 5.1. 

  
 11 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 5.3    Restrictions. During the Term and for [***] years
thereafter, Receiving Party shall keep all Disclosing Party’s Confidential Information in confidence with the same degree of care with which Receiving Party holds its own confidential information. Receiving Party shall not use Disclosing
Party’s Confidential Information except in connection with the performance of its obligations and exercise of its rights under this Agreement. Receiving Party has the right to disclose Disclosing Party’s Confidential Information without
Disclosing Party’s prior written consent, to the extent and only to the extent reasonably necessary, to Receiving Party’s affiliates and their employees, subcontractors, consultants or agents who have a need to know such Confidential
Information in order to perform Receiving Party’s obligations or exercise Receiving Party’s rights under this Agreement, provided said affiliates and their employees, subcontractors, consultants or agents are required to
comply with a written confidentiality agreement having restrictions on use and disclosure of Disclosing Party’s Confidential Information which are no less stringent than those in this Section 5.3 (other than with respect to the term of the
confidentiality obligations, which shall be at least [***] years from the date of disclosure). Receiving Party assumes responsibility for compliance with such restrictions by its affiliates and their employees, subcontractors, consultants or agents.

 5.4    Exceptions. Receiving Party’s obligation of nondisclosure and the limitations upon the right to
use the Disclosing Party’s Confidential Information shall not apply to the extent that Receiving Party can demonstrate, as evidenced by contemporaneous written records, that the Disclosing Party’s information: (i) was known to
Receiving Party or any of its affiliates prior to the time of disclosure; (ii) is or becomes public knowledge through no fault or omission of Receiving Party or any of its affiliates; (iii) is obtained by Receiving Party or any of its
affiliates from a Third Party under no obligation of confidentiality to Disclosing Party; (iv) has been independently developed by employees, subcontractors, consultants or agents of Receiving Party or any of its affiliates without the aid,
application or use of Disclosing Party’s Confidential Information or (v) is not Confidential Information under Section 5.1. 

5.5    Permitted Disclosures. Receiving Party may disclose Disclosing Party’s Confidential Information to the
extent (and only to the extent) such disclosure is reasonably necessary in the following instances: 
 5.5.1    in order
to comply with applicable law (including any securities law or regulation or the rules of a securities exchange) or with a legal or administrative proceeding; 

5.5.2    in connection with prosecuting or defending litigation, regulatory approvals and other regulatory filings and
communications, and filing, prosecuting and enforcing patents in connection with Receiving Party’s rights and obligations pursuant to this Agreement; and 

5.5.3    in connection with exercising its rights hereunder, to its affiliates; in the case of Company as the Receiving
Party, to potential and future collaborators and sublicensees; in the case of Company or Cellscript as the Receiving Party, to permitted acquirers or assignees; and investment bankers, investors and lenders, except that Cellscript will obtain the
prior written consent of Company before disclosing any information disclosed to Cellscript pursuant to Sections 2.1, 2.3, 3.3, 3.4.3(a), 4.1, 4.4, 4.6 and 6.6; 

provided that (1) with respect to Sections 5.5.1 or 5.5.2, where reasonably possible, Receiving Party shall notify Disclosing
Party of Receiving Party’s intent to make any disclosure pursuant thereto sufficiently prior to making such disclosure so as to allow Disclosing Party adequate time to take whatever action it may deem appropriate to protect the confidentiality
of the information to be disclosed, and (2) with respect to Section 5.5.3, each of those named people 

  
 12 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 
and entities are required to comply with the restrictions on use and disclosure in Section 5.3 (other than investment bankers, investors and lenders, which must be bound prior to disclosure
by commercially reasonable obligations of confidentiality). 
 5.6    Terms of this Agreement. The Parties agree
that the terms of this Agreement shall be treated as Confidential Information of both Parties, and thus may be disclosed only as permitted by Section 5.5. Each Party agrees not to issue any press release or public statement disclosing
information relating to this Agreement or the terms hereof without the prior written consent of the other Party not to be unreasonably withheld. 

5.7    Use of Penn’s, Cellscript’s or Company’s Name. Company and its Affiliates, Third Party
sublicensees, employees, and agents are not granted any rights hereunder to use the name, logo, seal, trademark, or service mark (including any adaptation of them) of Penn or any Penn school, or their respective organizations, employees, students or
representatives, without the prior written consent of Penn. Except to the extent permitted pursuant to this Article 5, neither Party shall have any right, express or implied, to use in any manner the name or other designation of the other Party or
any other trade name or trademark of the other Party for any Purpose, except as may be required by applicable law or regulation. 

6    TERM AND TERMINATION 

6.1    Term. This Agreement will commence on the Effective Date and terminate upon the expiration or abandonment of
the last patent to expire or become abandoned of the Patent Rights (the “Term”). 
 6.2    Early
Termination by Company. Company may terminate this Agreement at any time effective upon completion of each of the following conditions: (a) providing at least sixty (60) days prior written notice to Cellscript of such intention to terminate; (b)
ceasing to make, have made, use, import, offer for sale and sell all Licensed Products under the Sublicense; [***]. For clarity, Company may individually terminate either the Sublicense to Exhibit A-1 Patent
Rights or the Sublicense to Exhibit A-2 Patent Rights provided that each of the conditions stipulated in Section 6.2 is met with respect to the Patent Rights terminated from the Sublicense. [***] [***]

 6.3    Early Termination by Cellscript. Cellscript may, to the extent permissible by law, terminate this
Agreement if: (a) Company is more than [***] days late in paying to Cellscript any amounts owed under this Agreement and does not pay Cellscript in full, including accrued interest, within [***] days after receiving written notice of the breach
from Cellscript (a “Payment Default”); or (b) other than a Payment Default, Company materially breaches this Agreement and Company does not cure the breach within [***] days after receiving written notice of the breach from
Cellscript; or (c) Company causes or experiences a Trigger Event, [***]. It is understood that, with respect to both of (a) and (b), Company is also responsible for its Affiliates and Third Parties sublicensees. 

6.4    Trigger Event. The term “Trigger Event” means any of the following: (a) Company
(i) becomes insolvent, bankrupt or generally fails to pay its debts as such debts become due, (ii) is adjudicated insolvent or bankrupt, (iii) admits in writing its inability to pay its debts, (iv) suffers the appointment of a
custodian, receiver or trustee for its assets and, if appointed without its consent, not discharged within [***] days, (v) makes an assignment of its assets for the benefit of creditors, or (vi) suffers proceedings being instituted against
it under any law related to bankruptcy, insolvency, dissolution, liquidation or the reorganization, readjustment or release of multiple debtors and, if contested by it, not dismissed or stayed within [***] days; (b) the institution or
commencement by Company of any proceeding under any law related to bankruptcy, insolvency, liquidation or the reorganization, readjustment or release of multiple 

  
 13 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 
debtors; (c) the entering of any order for relief relating to any of the proceedings described in Section 6.4(a) or (b) above; (d) the calling by Company of a meeting of multiple
creditors with a view to arranging a composition of adjustment of its debts; (e) the act or failure to act by Company that results in its consent to, approval of, or acquiescence in any of the proceedings described in Section 6.4(a) - (d)
above; or (f) [***]. 
 6.5    Effect of Termination. 

6.5.1    Effect of Termination Except under Section 6.2. Upon the termination of this Agreement
prior to expiration of the Term for any reason except pursuant to Section 6.2: (a) the Sublicense to the Patent Rights and Exhibit D Patents will terminate; (b) [***] (c) Company will pay to Cellscript all amounts, including accrued interest,
owed to Cellscript under this Agreement through the date of termination, including royalties on Licensed Products invoiced or shipped through the date of termination and any sell off period permitted by Section 6.6, whether or not payment is
received prior to termination or expiration of the sell off period permitted by Section 6.6; (d) Company will, at Cellscript’s request, return to Cellscript all confidential information of Cellscript (if any) related to exploitation of
Patent Rights and Exhibit D Patents and [***]; (e) in the case of termination under Section 6.3, all duties of Cellscript and all rights (but not duties) of Company under this Agreement immediately terminate without further action required by
either Cellscript or Company; and (f) all outstanding Third Party sublicenses, to the extent each is not in default, will be assigned by Company to Cellscript, [***], and each Third Party sublicense agreement will remain in full force and
effect [***], but the duties and obligations of Cellscript under the [***] sublicense agreements will not be greater than the duties of Cellscript under this Agreement and the rights of Cellscript under the [***] sublicenses will not be less than
those of Cellscript under this Agreement, including [***]. Notwithstanding the foregoing, in the event the Cellscript Sublicense Agreement is terminated and said termination of the Cellscript Sublicense Agreement is not due to any act or omission of
Company or its Affiliates or Third Party sublicensees and, to the extent the Company is not in default under the Sublicense, Cellscript will assign this Agreement to mRNA RiboTherapeutics, such assignment will be accepted by mRNA RiboTherapeutics
and this Agreement and each of Company’s further sublicense agreements, to the extent each said further sublicense is not in default, will remain in full force and effect (including with respect to the sublicensed Exhibit A-1 Patent Rights and Exhibit A-2 Patent Rights and Exhibit D Patents), with mRNA RiboTherapeutics as the sublicensor to Company instead of Cellscript, but the duties and
obligations of mRNA RiboTherapeutics under the assigned Sublicense and the Company’s further sublicenses will not be greater than the duties of Cellscript under this Agreement, and the rights of mRNA RiboTherapeutics under the assigned
Sublicense and Company’s further sublicenses will not be less than the rights of Cellscript under this Agreement, [***]. 

6.5.2    Effect of Termination under Section 6.2. Upon the termination of this Agreement under
Section 6.2: (a) the Sublicense to Company and all further sublicenses to Affiliates and Third Parties terminate (except to the extent that said Third Party sublicenses [***] (b) [***]; (c) Company will pay to Cellscript all amounts, including
accrued interest, owed to Cellscript under this Agreement through the date of termination, including royalties on Licensed Products invoiced or shipped through the date of termination and any sell off period permitted by Section 6.6, whether or
not payment is received prior to termination or expiration of the sell off period permitted by Section 6.6, and (d) Company will, at Cellscript’s request, return to Cellscript all confidential information of Cellscript; and
(e) all outstanding sublicenses of Company to Third Parties and all outstanding sublicenses of Company’s Affiliates to Third Parties, to the extent each is not in default, will be assigned [***] to Cellscript [***], and each such assigned

  
 14 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 
sublicense agreement will remain in full force and effect [***], but the duties and obligations of Cellscript under the [***] sublicense agreements will not be greater than the duties and
obligations of Company under this Agreement, and the rights of Cellscript under the [***] sublicense agreements will not be less than the rights of Company under this Agreement, including [***], and Cellscript may, [***]. 

6.6    Inventory & Sell Off. Subject to the remainder of this Section 6.6, upon the
termination of this Agreement for any reason, Company will: (1) cause physical inventories to be taken [***] of: (a) all completed Licensed Products on hand under the control of Company and its Affiliates and Third Party sublicensees and
(b) such Licensed Products as are in the process of manufacture and any component parts on the date of termination of this Agreement; (2) deliver promptly to Cellscript a copy of said written inventory, [***]; (3) promptly remove, efface
or destroy or require or cause to be removed, effaced or destroyed all references to Penn and Cellscript from any advertising, labels, web sites or other materials used in the promotion of the business of Company or its Affiliates or Third Party
sublicensees; and (4) [***]. Subject to this Section 6.6, Company and its Affiliates and Third Party sublicensees may sell off its inventory of Licensed Products existing on the date of termination for a period of [***] months and pay
Cellscript royalties on Sales of such inventory within [***] days following the expiration of such [***] month period. Notwithstanding the foregoing: (i) Company’s obligations under this Section 6.6 will not apply to the Sublicense or
to Company’s sublicense agreements if the Sublicense is assigned to mRNA RiboTherapeutics pursuant to Section 6.5.1; and (ii) the obligations of each of Company’s sublicensees pursuant to this Section 6.6 will not apply to
Company’s or its Affiliates’ or Third Party sublicensees’ sublicense agreements that are assigned to Cellscript pursuant to Sections 6.5.1(f) or 6.5.2(e); and, (iii) Company’s and its Affiliates’ and Third Party
sublicensees’ obligations under this Section 6.6 will not apply with respect to any Licensed Product that is for use in a Field of Use for which Company (and its Affiliates or Third Party sublicensees) has a different sublicense agreement
[***]. 
 6.7    Survival. Company’s obligation to pay all amounts, including accrued interest, owed to
Cellscript under this Agreement will survive the termination of this Agreement for any reason. [***] will survive the termination of this Agreement in accordance with their respective terms. The Parties acknowledge and agree that the Sublicense is,
for the purposes of section 365(n) of the U.S. Bankruptcy Code, a license to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy Code. The Parties intend that all payments under Article 3 of this Agreement
constitute “royalties” within the meaning of section 365(n) of the U.S. Bankruptcy Code. 
 7    PATENT PROSECUTION AND
MAINTENANCE 
 7.1    Patent Control for Patent Rights. [***] control the preparation, prosecution and
maintenance of the Patent Rights and the selection of patent counsel, subject to the remainder of this Section 7.1. For purposes of this Section 7.1, the word “maintenance” includes any interference negotiations, claims, or
proceedings, in any forum, [***]), a Third Party, or the United States Patent and Trademark Office or any foreign equivalent pertaining to Patent Rights, and any requests [***] that the United States Patent and Trademark Office or any foreign
equivalent reexamine or reissue any patent in the Patent Rights. Notwithstanding the foregoing, [***] will provide [***] and its counsel with reasonable opportunities to consult with [***] regarding prosecution and maintenance of Patent Rights. 

7.2    Patent Control for Exhibit D Patents. [***] control the preparation, prosecution and maintenance of the
Exhibit D Patents and the selection of patent counsel, subject to the 

  
 15 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 
remainder of this Section 7.2. For purposes of this Section 7.2, the word “maintenance” includes any interference negotiations, claims, or proceedings, in any forum, [***], a
Third Party, or the United States Patent and Trademark Office pertaining to Exhibit D Patents, and any requests [***] that the United States Patent and Trademark Office reexamine or reissue any patent in the Exhibit D Patents. Notwithstanding the
foregoing, [***] will provide [***] and its counsel with reasonable opportunities to consult with [***] regarding prosecution and maintenance of Exhibit D Patents. 

8    INFRINGEMENT 

8.1    Control. [***] 

8.2    Cooperation. In any litigation under this Article 8, each Party, at the reasonable request and sole
expense of the other Party, will provide reasonable cooperation to such other Party. This Article 8 will not be construed to require either Party to undertake any activities, including legal discovery, at the request of any Third Party, except
as may be required by lawful process of a court of competent jurisdiction. 
 9    REPRESENTATIONS, WARRANTIES, COVENANTS AND
DISCLAIMER OF WARRANTIES 
 9.1    Covenants of Cellscript. Cellscript covenants to Company that, during the
Term: 
 9.1.1    Cellscript will take all reasonable actions necessary to maintain Cellscript’s rights under the
Cellscript Sublicense Agreement and to the extent within its power, will ensure that the rights granted to Company herein are maintained. 

9.1.2    In the event of termination of the Cellscript Sublicense Agreement, this Agreement will be assigned to mRNA
RiboTherapeutics without any further action by the Parties, and the sublicenses granted hereunder, to the extent they are not in breach or default, will remain in full force and effect with respect to the sublicensed Exhibit A-1 Patent Rights, Exhibit A-2 Patent Rights and Exhibit D Patents. 

9.1.3    Cellscript will use diligent efforts not to breach the Cellscript Sublicense Agreement, and to the extent within
its legal power, will ensure that its sublicensed affiliates do not breach or cause a breach of any sublicense under the Cellscript Sublicense Agreement that would result in mRNA RiboTherapeutics having the right to terminate the Cellscript
Sublicense Agreement or Penn having the right to terminate the Penn License Agreement, and, in the event of any such breach, Cellscript will use diligent efforts to expeditiously cure (or cause to be cured) any such breach. 

9.1.4    Upon Cellscript learning of any breach of a sublicense agreement by any sublicensee of Cellscript or any of its
further sublicensees that would result in mRNA RiboTherapeutics having the right to terminate the Cellscript Sublicense Agreement or Penn having the right to terminate the Penn License Agreement, Cellscript will expeditiously take appropriate
actions to stop such act or omission, up to and including termination of the applicable sublicense, as stated in Section 1.5.4 of the Cellscript Sublicense Agreement. 

9.1.5    Cellscript will make all payments due under the Cellscript Sublicense Agreement and will make all required
disclosures to mRNA RiboTherapeutics in connection therewith, in each case in a timely manner in accordance with the terms thereof. 

  
 16 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 9.1.6    Promptly following Cellscript’s or any of its
affiliates’ receipt of any material written notice or correspondence pertaining to the Sublicense that would reasonably be expected to adversely affect Company’s rights under this Agreement, Cellscript will, to the extent permissible,
furnish a copy of such notice or correspondence to Company, provided that Cellscript may redact portions of any such notice or correspondence that do not relate to or impact Company’s rights hereunder. 

9.1.7    Cellscript will promptly notify Company if Cellscript receives a notice from mRNA RiboTherapeutics or Penn of
intent to terminate the Penn License Agreement. 
 9.1.8    Cellscript agrees that Cellscript and its affiliates will
not sue, bring an action against, or otherwise assert any claim against Company or its Affiliates or Third Party sublicensees or their successors in ownership (to which this Agreement or a sublicense under this Agreement is assigned according to
terms and conditions for assignment pursuant to Section 15.5 or Section 1.5.5 herein) for infringement of or misappropriation of any Patent Rights (as defined in Section 1.2) or Exhibit D Patents (as defined in Section 1.7) that
are used by Company or its Affiliates or Third Party sublicensees or their successors in ownership in the In Vivo Field of Use (as defined in Section 1.2) within Sublicensed Fields of Use. For clarity, the foregoing covenant [***]. For
further clarity, [***]. This covenant shall terminate with the termination of this Agreement unless the termination is: [***] (“Contested Termination”). In the event of a Contested Termination, this covenant shall continue
to run during the [***] days, and if a lawsuit is initiated, until said state or federal court enters a final decision from which no appeal has been or can be taken. 

9.1.9    Cellscript will not amend the Cellscript Sublicense Agreement in any manner that would negatively affect the
rights and/or obligations of the Company under this Agreement. Following execution of any amendment to the Cellscript Sublicense Agreement that pertains to or impacts Company or its rights hereunder, Cellscript agrees that it will provide a copy of
same to Company, except that Cellscript may redact portions of any such amendment that do not relate to or impact Company or its rights hereunder in any way. 

9.1.10    To the extent within its rights and legal power, Cellscript will not exercise any right to terminate the
Cellscript Sublicense Agreement in whole or in part. 
 9.1.11    [***] 

9.2    Covenants of mRNA RiboTherapeutics. mRNA RiboTherapeutics covenants to Company as follows: 

9.2.1    mRNA RiboTherapeutics will not terminate the Cellscript Sublicense Agreement without good and reasonable cause.

 9.2.2    In the event of termination of the Cellscript Sublicense Agreement, provided that Company did not cause said
termination of the Cellscript Sublicense Agreement and is not in breach or default under this Agreement, this Agreement will be assigned to mRNA RiboTherapeutics without any further action by Cellscript, mRNA RiboTherapeutics will accept such
assignment of this Agreement and this Agreement, including all of Company’s outstanding Third Party sublicenses thereunder, will remain in full force and effect with respect to the sublicensed Exhibit A-1
Patent Rights, Exhibit A-2 Patent Rights, with mRNA RiboTherapeutics as the sublicensor instead of Cellscript, but the duties and obligations of mRNA RiboTherapeutics under the assigned Agreement will not be
greater than the duties of Cellscript under this Agreement and the rights (including all financial consideration and other rights) of mRNA RiboTherapeutics under the assigned Agreement will not be less than those of Cellscript

  
 17 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 
under this Agreement, and mRNA RiboTherapeutics may, at its sole discretion, amend this Agreement to contain terms and conditions found in the Cellscript Sublicense Agreement. 

9.2.3    Upon mRNA RiboTherapeutics learning of any breach of a sublicense agreement by any sublicensee or any further
sublicensees thereof in any manner that would result in mRNA RiboTherapeutics having the right to terminate the Cellscript Sublicense Agreement or Penn having the right to terminate the Penn License Agreement, mRNA RiboTherapeutics will
expeditiously take appropriate actions to stop such act or omission, up to and including termination of the applicable sublicense. 

9.2.4    mRNA RiboTherapeutics will make all payments due under the Penn License Agreement and will make all required
disclosures to Penn in connection therewith, in each case in a timely manner in accordance with the terms thereof. 

9.2.5    Promptly following mRNA RiboTherapeutics’ or any of its affiliates’ receipt of any material written
notice or correspondence pertaining to the Company’ sublicense agreement from Cellscript that would reasonably be expected to adversely affect Company’s rights thereunder, mRNA RiboTherapeutics will, to the extent permissible, furnish a
copy of such notice or correspondence to Cellscript and to Company, provided that mRNA RiboTherapeutics, as applicable, may redact portions of any such notice or correspondence that do not relate to or impact Company’s rights. 

9.2.6    mRNA RiboTherapeutics will promptly notify Cellscript and Company if it receives a notice from Penn of intent to
terminate the Penn License Agreement. 
 9.2.7    mRNA RiboTherapeutics agrees that mRNA RiboTherapeutics and its
affiliates will not sue, bring an action against, or otherwise assert any claim against Company or its Affiliates or Third Party sublicensees or their successors in ownership (to which this Agreement or a sublicense under this Agreement is assigned
according to terms and conditions for assignment pursuant to Section 15.5 or Section 1.5.5 herein) for infringement of or misappropriation of any Patent Rights (as defined in Section 1.2) that are used by Company or its Affiliates or
Third Party sublicensees or their successors in ownership in the In Vivo Field of Use [***]. This covenant shall terminate with the termination of this Agreement unless the termination is a Contested Termination. In the event of a
Contested Termination, this covenant shall continue to run during the [***] days, and if a lawsuit is initiated, until said state or federal court enters a final decision from which no appeal has been or can be taken. 

9.2.8    mRNA RiboTherapeutics will not amend the Cellscript Sublicense Agreement in any manner that would negatively
affect the rights and/or obligations of the Company under this Agreement. 
 9.2.9    [***] 

9.3    Covenants of Company. Company covenants to Cellscript and to mRNA RiboTherapeutics that, during the Term:

 9.3.1    Upon Company learning of any breach of a sublicense agreement by any of its Affiliates or Third Party
sublicensees in any manner that would result in mRNA RiboTherapeutics having the right to terminate the Cellscript Sublicense Agreement or Penn having the right to terminate the Penn License Agreement, Company will [***]. 

9.3.2    Company will not breach this Agreement, and to the extent within its legal power, will ensure that its Affiliates
do not breach or cause breach of any sublicense under this Agreement, in any manner that would [***]. 

  
 18 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 9.3.3    Company will pay all payments due under this Agreement pursuant
to Article 3 and in accordance with the terms in Articles 3 and Section 4.2 and will provide all information, reports and notices required in accordance with Sections 2.1, 2.3, 3.3, 3.4.3(a), 4.1, 4.4 and 6.6 and in the form of the sample
report attached as Exhibit C, in each case in accordance with the time periods set forth therein. 
 9.3.4    Promptly
following Company’s or any of its Affiliates’ receipt of any material written notice or correspondence pertaining to the Sublicense that would reasonably be expected to adversely affect Cellscript’s rights or obligations under this
Agreement, Company will, to the extent permissible, furnish a copy of such notice or correspondence to Cellscript, provided that Company may redact portions of any such notice or correspondence that do not relate to or impact Cellscript ’s
rights hereunder. 
 9.3.5    Company will promptly notify Cellscript if Company receives [***]. 

9.3.6    [***] 

9.4    Representations and Warranties of Cellscript. As of the Effective Date, Cellscript, on behalf of itself and
its affiliates, hereby represents and warrants to Company that: 
 9.4.1    (a) either Cellscript or mRNA
RiboTherapeutics has provided Company with a copy of a true and correct copy of the Cellscript Sublicense Agreement (including all exhibits and amendments thereto), which has been redacted only with respect to the numerical values of the
compensation payable thereunder and certain terms and conditions that do not pertain to and that are immaterial to Company’s rights in the Sublicensed Fields of Use, (b) prior to the Effective Date, mRNA RiboTherapeutics has provided
Company with an opportunity to view a copy of the Cellscript Sublicense Agreement (including all exhibits and amendments thereto) which is true, correct and complete except for being redacted only with respect to the amounts paid or payable by
Cellscript to mRNA RiboTherapeutics for said sublicense and the milestones and other fees and royalties payable by Cellscript for the Ex Vivo Field of Use; (c) either Cellscript or mRNA RiboTherapeutics has provided Company with a true
and correct copy of the Penn License Agreement (including all exhibits and amendments thereto) which has been redacted only with respect to the numerical values of the compensation payable thereunder and certain terms and conditions that do not
pertain to and that are immaterial to Company’s rights in the Sublicensed Fields of Use or the fields of use sublicensed to Company under the mRNA RiboTherapeutics Sublicense Agreement, (d) prior to the Effective Date, mRNA
RiboTherapeutics has provided Company with an opportunity to view a true and correct and copy of the Penn License Agreement (including all exhibits and amendments thereto) which has been redacted only with respect to [***], (d) except for [***],
there is no other outstanding license, sublicense agreement, written or verbal, for Patent Rights in Field of Use B between Cellscript or mRNA RiboTherapeutics (or any affiliate thereof) on the one hand and Penn on the other hand, or between
Cellscript (or any affiliate thereof) and mRNA RiboTherapeutics (or any affiliate thereof). 
 9.4.2    (a) Neither
Cellscript nor any affiliate thereof has [***]; (b) except for (i) this Agreement to Company, (ii) the Cellscript Sublicense Agreement; (iii) the mRNA RiboTherapeutics Sublicense Agreement to Company, [***]; and (c) Cellscript
has not granted any liens or encumbrances in or to its rights in Patent Rights or the Cellscript Sublicense Agreement. 

  
 19 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 9.4.3    Cellscript has not breached or defaulted under any provision of
the Cellscript Sublicense Agreement in any material respect or received any written notice from mRNA RiboTherapeutics of any claims for indemnification pursuant thereto. 

9.4.4    To the knowledge of Cellscript, (a) there are no facts that would preclude Penn from having clear title to
the Patent Rights, (b) there are no pending or threatened litigations, interferences, reexaminations, oppositions or like procedures involving any such Patent Rights and (c) all of the issued patents within the Patent Rights are valid and
enforceable, are in full force and effect and have not lapsed, expired or otherwise terminated. 
 9.4.5    Cellscript
believes the terms and conditions of this Agreement are [***] consistent with the terms and conditions of the Cellscript Sublicense and the Penn License Agreement; 

9.4.6    Cellscript has not received any written notice of any claim by any person or entity challenging the sublicense
rights of Cellscript or the validity or enforceability of the Patent Rights. 
 9.4.7    [***] 

9.4.8    Cellscript believes that the representations and warranties of Cellscript in this Agreement, do not, taken as a
whole, (i) contain any untrue statement of a material fact; or (ii) omit to state any material fact necessary to make the statements or facts contained therein, in light of the circumstances under which they were made, not misleading.
Cellscript has not knowingly withheld any information with respect to the Cellscript Sublicense Agreement, the Penn License Agreement or the Patent Rights that would reasonably be expected to be material to Company’s decision to enter into this
Agreement. 
 9.5    Representations and Warranties of mRNA RiboTherapeutics. As of the Effective Date, mRNA
RiboTherapeutics, on behalf of itself and its affiliates, hereby represents and warrants to Company that: 

9.5.1    (a) either Cellscript or mRNA RiboTherapeutics has provided Company with a copy of a true and correct copy of the
Cellscript Sublicense Agreement (including all exhibits and amendments thereto), which has been redacted with respect to the numerical values of the compensation payable thereunder and certain terms and conditions that do not pertain to and that are
immaterial to Company’s rights in the Sublicensed Fields of Use, (b) prior to the Effective Date, either mRNA RiboTherapeutics or Cellscript has provided Company with an opportunity to view a copy of the Cellscript Sublicense Agreement
(including all exhibits and amendments thereto) which is true, correct and complete except for being redacted only with respect to the amounts paid or payable by Cellscript to mRNA RiboTherapeutics for said sublicense and the milestones and other
fees and royalties payable by Cellscript for the Ex Vivo Field of Use; (c) either Cellscript or mRNA RiboTherapeutics has provided Company with a true, correct and complete copy of the Penn License Agreement (including all exhibits and
amendments thereto), which has been redacted with respect to the numerical values of the compensation payable thereunder and certain terms and conditions that do not pertain to and that are immaterial to Company’s rights in the Sublicensed
Fields of Use or the fields of use sublicensed to Company under the mRNA RiboTherapeutics Sublicense Agreement, (d) prior to the Effective Date, mRNA RiboTherapeutics has provided Company with an opportunity to view a true and correct copy of
the Penn License Agreement (including all exhibits and amendments thereto) which has been redacted only with respect to [***], there are no other license, sublicense or other agreements, written or verbal, relating to the Patent Rights between
Cellscript or mRNA 

  
 20 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 
RiboTherapeutics (or any affiliate thereof) on the one hand and Penn on the other hand, or between Cellscript (or any affiliate thereof) and mRNA RiboTherapeutics (or any affiliate thereof). 

9.5.2    (a) Neither mRNA RiboTherapeutics nor any affiliate thereof has [***]; (b) except for (i) the Cellscript
Sublicense Agreement; (ii) this Agreement to Company, (iii) the mRNA RiboTherapeutics Sublicense Agreement to Company, (iv) [***], and (v) [***]; and (c) neither mRNA RiboTherapeutics nor any affiliate thereof has granted any liens or
encumbrances in or to its rights in Patent Rights or the Cellscript Sublicense Agreement. 
 9.5.3    Cellscript has not
breached or defaulted under any provision of the Cellscript Sublicense Agreement in any material respect or received any written notice from mRNA RiboTherapeutics of any claims for indemnification pursuant thereto and mRNA RiboTherapeutics
has not breached or defaulted under any provision of the Penn License Agreement in any material respect or received any written notice from Penn of any claims for indemnification pursuant thereto. 

9.5.4    To the knowledge of mRNA RiboTherapeutics, (a) there are no facts that would preclude Penn from having clear
title to the Patent Rights, (b) there are no pending or threatened litigations, interferences, reexaminations, oppositions or like procedures involving any such Patent Rights and (c) all of the issued patents within the Patent Rights are
valid and enforceable, are in full force and effect and have not lapsed, expired or otherwise terminated. 

9.5.5    mRNA RiboTherapeutics believes the terms and conditions of this Agreement are [***] consistent with the terms and
conditions of the Cellscript Sublicense Agreement and the Penn License Agreement. 
 9.5.6    mRNA RiboTherapeutics has
not received, any written notice of any claim by any person or entity challenging the sublicense rights of Cellscript or the validity or enforceability of the Patent Rights. 

9.5.7    [***] 

9.5.8    mRNA RiboTherapeutics believes that the representations and warranties of mRNA RiboTherapeutics in this
Agreement, do not, taken as a whole, (i) contain any untrue statement of a material fact; or (ii) omit to state any material fact necessary to make the statements or facts contained therein, in light of the circumstances under which they
were made, not misleading. mRNA RiboTherapeutics has not knowingly withheld any information with respect to the Cellscript Sublicense Agreement, the Penn License Agreement or the Patent Rights that would reasonably be expected to be material
to Company’s decision to enter into this Agreement. 
 9.6    Representations and Warranties of
Company. Company, on behalf of itself and its affiliates, hereby represents and warrants to Cellscript and to mRNA RiboTherapeutics that, as of the Effective Date:  

9.6.1    Company is duly organized and validly existing under the laws of the jurisdiction of its incorporation and has
full corporate power and authority to enter into this Agreement. 
 9.6.2    Company is in good standing with all
relevant governmental authorities. 
 9.6.3    Company has taken all corporate actions necessary to authorize the
execution and delivery of this Agreement and the performance of its obligations under this Agreement. 

  
 21 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 9.6.4    The performance of its obligations under this Agreement do not
conflict with or constitute a default under its charter documents, any contractual obligation of Company or any court order. 

9.6.5    [***] 

9.6.6    [***] 

9.6.7    Company has read the copy of the Penn License Agreement (including all exhibits and amendments thereto) that was
provided to Company by mRNA RiboTherapeutics or Cellscript. 
 9.6.8    Company has read the redacted copy of the
Cellscript Sublicense (including all exhibits and amendments thereto) that was provided to Company by Cellscript or mRNA RiboTherapeutics. 

9.6.9    Company believes that the representations and warranties of Company in this Agreement, do not, taken as a whole,
(i) contain any untrue statement of a material fact; or (ii) omit to state any material fact necessary to make the statements or facts contained therein, in light of the circumstances under which they were made, not misleading. Company has not
knowingly withheld any information with respect to the any of Company’s above statements that would reasonably be expected to be material to Cellscript’s decision to enter into this Agreement. 

9.7    Disclaimer of Warranties. EXCEPT AS SPECIFICALLY SET FORTH IN THIS ARTICLE 9, NO PARTY MAKES ANY
REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS OR SUFFICIENCY OF PATENT RIGHTS OR EXHIBIT D PATENTS FOR A PARTICULAR PURPOSE, APPLICATION OR USE,
NON-INFRINGEMENT, OR ANY OTHER STATUTORY WARRANTY. 
 10    ADDITIONAL TERMS REGARDING
SUBLICENSING 
 10.1    Purpose of this Article. This Article 10 sets forth terms and conditions for further
sublicensing by Primary Sublicensors in the Human In Vivo Therapeutics Field, wherein, for the purposes of this Article 10: 
  

	 	(a)	 “sublicensing” herein means any grant of a sublicense, covenant not to sue, or option for
current or future rights under Patent Rights, and the noun “sublicense” herein means a document that grants such sublicense, covenant not to sue, or option for current or future rights under Patent Rights; 

 

	 	(b)	 “Primary Sublicensors” herein means (i) mRNA RiboTherapeutics, (ii) Cellscript, and
(iii) any affiliate of (i) or (ii) that is granted a sublicense in the Human In Vivo Therapeutics Field; and 

  

	 	(c)	 “[***]” herein means any or all therapeutic and prophylactic use(s) in [***].

 For clarity and the absence of doubt, Article 10 shall not be interpreted in any way so as to limit, restrict or impose
any terms or conditions on Primary Sublicensors’ rights to grant sublicenses under Patent Rights to any party at any time for any Field of Use other than the Human In Vivo Therapeutics Field. 

  
 22 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 10.2    Human In Vivo Therapeutics Field
Sublicenses. Subject to the rights of the Primary Sublicensors and their respective owners under Section 10.4, Cellscript, mRNA RiboTherapeutics and Company agree that, from the Effective Date until [***], mRNA RiboTherapeutics and
Cellscript will not grant and will ensure that other Primary Sublicensors will not grant Human In Vivo Therapeutics Field Sublicenses[***]. 

“Human In Vivo Therapeutics Field Sublicense” means a sublicense to make, have made, use, import,
offer for sale, sell and/or have sold any number of products [***] for the Human In Vivo Therapeutics Field, [***]. 

10.3    Product Sublicenses. Subject to the rights of the Primary Sublicensors and their respective owners under
Section 10.4, Cellscript, mRNA RiboTherapeutics and Company agree that, from the Effective Date until [***], Cellscript and mRNA RiboTherapeutics will (and will ensure that the other Primary Sublicensors will): 

(a)    grant Product Sublicenses only to [***], 

wherein “Product Sublicenses” herein mean sublicenses under Patent Rights to research, develop, manufacture and/or
commercialize specific products [***], for a therapeutic or prophylactic use in humans in the In Vivo Field of Use, and 
 wherein
“[***]” herein means [***]: 
  

	 	(i)	 [***] 

  

	 	(ii)	 [***] 

  

	 	(iii)	 [***] 

(b)    only grant [***] Sublicenses for [***] 

(c)    except as set forth in Sections 10.2 and 10.3, not otherwise grant sublicenses under the Patent Rights to research,
develop, manufacture and/or commercialize [***] [***]. 
 10.4    Sale of a Primary Sublicensor. Company
understands and agrees that the owners of each of mRNA RiboTherapeutics and Cellscript shall have the right to sell all or any part of the outstanding stock or ownership interest or the business or the assets thereof, as applicable, of mRNA
RiboTherapeutics and/or Cellscript [***] at any time and without any conditions pursuant to this Agreement other than the requirements under Section 15.5, 

except that, as a condition to any such sale occurring prior to [***]: 

(a)    the owners of each of mRNA RiboTherapeutics and Cellscript [***] sell mRNA RiboTherapeutics or Cellscript to [***];
and 
 (b)    without in any way negating or ceding or giving up any of their current rights to sell all or any part of
the stock, ownership interest, business or assets of mRNA RiboTherapeutics and/or Cellscript or to discuss any such sale with any potential purchaser at any time, including from the Effective Date of this Agreement [***], the owners of mRNA
RiboTherapeutics and Cellscript agree not to [***] prior to [***], 
 wherein “[***]” herein means [***]; and 

for the avoidance of doubt, Company agrees that this Section 10.4(a) shall not be interpreted so as to prohibit the owners of mRNA
RiboTherapeutics and/or Cellscript from [***]; 
 (c)    the purchaser of mRNA RiboTherapeutics or Cellscript,
respectively, will pay [***]; 

  
 23 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 (d)    on the effective date of any such sale of [***], the purchased
company (whether mRNA RiboTherapeutics or Cellscript) and the purchaser and their assignees and successors in ownership thereof shall [***]: 
  

	 	(i)	 grant [***] Sublicenses to affiliates and Third Parties [***], and 

 

	 	(ii)	 grant [***] Sublicenses to affiliates and any Third Parties to research, develop, manufacture and/or
commercialize any number of products [***] without being subject to any of the restrictions, limitations or requirements that the sublicensee is [***] as is required of the Primary Sublicensors in Section 10.3; and 

(d)    on the effective date of any such sale of more than fifty percent (50%) of the outstanding stock or ownership
interest or all of the business or assets of mRNA RiboTherapeutics or Cellscript [***], all of the rights of the Primary Sublicensors to grant Product Sublicenses pursuant to Section 10.3 shall remain only with the Primary Sublicensors for
which their stock, ownership interest, business and assets were not sold. 
 [***] 

10.5    From [***], Primary Sublicensors and any owners, assignees or successors in ownership thereof shall have the right
to grant [***] of [***] Sublicense(s) to any parties without any conditions (other than those imposed by the Penn License Agreement or the Cellscript Sublicense) and to grant any number of Product Sublicenses or any other sublicenses of any kind
under Patent Rights to any parties without any limitations or restrictions or requirements whatsoever under this Article 10. 

11    LIMITATION OF LIABILITY; DISCLAIMER. 

11.1    Limitation of Liability. CELLSCRIPT, mRNA RIBOTHERAPEUTICS AND PENN WILL NOT BE LIABLE TO COMPANY, ITS
AFFILIATES, SUBLICENSEES, SUCCESSORS OR ASSIGNS, OR ANY THIRD PARTY WITH RESPECT TO ANY CLAIM: ARISING FROM COMPANY’S USE OF THE PATENT RIGHTS, EXHIBIT D PATENTS, LICENSED PRODUCTS OR ANY OTHER TECHNOLOGY LICENSED UNDER THIS AGREEMENT; OR
ARISING FROM THE COMPANY’S, COMPANY’S AFFILIATES’ OR COMPANY’S SUBLICENSEES’ DEVELOPMENT, TESTING, MANUFACTURE, USE OR SALE OF LICENSED PRODUCTS. NOTWITHSTANDING ANYTHING IN THIS AGREEMENT OR OTHERWISE, NONE OF CELLSCRIPT,
mRNA RIBOTHERAPEUTICS, PENN, OR COMPANY WILL BE LIABLE TO THE OTHER OR ANY THIRD PARTY WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT FOR ANY INDIRECT, PUNITIVE, SPECIAL OR CONSEQUENTIAL DAMAGES, EVEN IF SUCH PARTY HAS BEEN INFORMED OR SHOULD
HAVE KNOWN OF THE POSSIBILITY OF SUCH DAMAGES; PROVIDED THAT THIS SECTION 11.1 WILL NOT APPLY: (a) TO A PARTY’S INDEMNIFICATION RIGHTS AND OBLIGATIONS UNDER ARTICLE 12 OR ARTICLE 13; (b) IN CIRCUMSTANCES OF GROSS NEGLIGENCE OR INTENTIONAL
MISCONDUCT BY A PARTY OR ITS AFFILIATES; OR (c) WITH RESPECT TO A PARTY’S LIABILITY FOR BREACH OF ARTICLE 5 or 10. 

11.2    Disclaimer. THE PATENT RIGHTS, EXHIBIT D PATENTS, LICENSED PRODUCTS AND ANY OTHER TECHNOLOGY LICENSED UNDER
THIS AGREEMENT ARE PROVIDED ON AN “AS IS” BASIS. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NONE OF CELLSCRIPT, mRNA RIBOTHERAPEUTICS, PENN, OR COMPANY MAKE ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR

  
 24 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 
IMPLIED, INCLUDING BUT NOT LIMITED TO ANY WARRANTY OF ACCURACY, COMPLETENESS, PERFORMANCE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, COMMERCIAL UTILITY,
NON-INFRINGEMENT, VALIDITY OR TITLE. 
 12    PENN INDEMNIFICATION 

12.1    Indemnification. Company will defend, indemnify, and hold harmless each Penn Indemnified Party from and
against any and all Penn Liabilities with respect to an Indemnification Event. The term “Penn Indemnified Party” means each of Penn and its trustees, officers, faculty, students, employees, contractors, and agents. For clarity,
Cellscript is not a Penn Indemnified Party. The term “Penn Liabilities” means all damages, awards, deficiencies, settlement amounts, defaults, assessments, fines, dues, penalties, costs, fees, liabilities, obligations, taxes, liens,
losses, lost profits and expenses (including, but not limited to, court costs, interest and reasonable fees of attorneys, accountants and other experts) that are incurred by a Penn Indemnified Party or awarded or otherwise required to be paid to
Third Parties by a Penn Indemnified Party. The term “Indemnification Event” means any Claim against one or more Penn Indemnified Parties arising out of or resulting from: [***]. The term “Claim” in
this Article 12 means any charges, complaints, actions, suits, proceedings, hearings, investigations, claims or demands. 

12.2    Reimbursement of Costs. Company will pay directly all Penn Liabilities incurred for defense or negotiation
of any Claim or will reimburse Penn for all documented Penn Liabilities incident to the defense or negotiation of any Claim within [***] days after Company’s receipt of invoices for such fees, expenses and charges. 

12.3    Control of Litigation. Company controls any litigation or potential litigation involving the defense of any
Claim, including the selection of counsel, with input from Penn. Penn reserves the right to protect its interest in defending against any Claim by selecting its own counsel, with any attorneys’ fees and litigation expenses paid for by Company,
pursuant to Sections 12.1 and 12.2. 
 12.4    Other Provisions. Company will not settle or compromise any Claim
giving rise to Penn Liabilities in any manner that imposes any restrictions or obligations on Penn or grants any rights to the Patent Rights, Exhibit D Patents or the Licensed Products without Penn’s prior written consent. If Company fails or
declines to assume the defense of any Claim within [***] days after notice of the Claim, or fails to reimburse a Penn Indemnified Party for any Penn Liabilities pursuant to Sections 12.1 and 12.2 within the [***] day time period set forth in
Section 12.2, then Penn may assume the defense of such Claim for the account and at the risk of Company, and any Penn Liabilities related to such Claim will be conclusively deemed a liability of Company. The indemnification rights of the Penn
Indemnified Parties under this Article 12 are in addition to all other rights that a Penn Indemnified Party may have at law, in equity or otherwise. 

  
 25 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 13    OTHER INDEMNIFICATION 

13.1     Indemnification by Company. Company will indemnify, defend and hold harmless Cellscript and its affiliates,
and its or their respective directors, officers, employees and agents (“Cellscript Indemnified Parties”), from and against any and all liabilities, damages, losses, costs and expenses including the reasonable fees of attorneys
(collectively “Losses”) arising out of or resulting from any and all Third Party suits, claims, actions, proceedings, payment obligations or demands (“Claims” in this Article 13) to the extent based upon:

 13.1.1     [***] 

13.1.2     [***] 

13.1.3     [***] 

except, in each case above, to the extent such Claim arose out of or resulted from or is attributable to any acts or omissions of Cellscript
or its directors, officers, employees and agents, or other circumstances for which Cellscript has an indemnity obligation pursuant to Section 13.2 below. 

13.2    Indemnification by Cellscript. Cellscript will indemnify, defend and hold harmless Company and its
affiliates, and its or their respective directors, officers, employees and agents (“Company Indemnified Parties”), from and against any and all Losses arising out of or resulting from any and all Claims to the extent based upon:

 13.2.1    [***] 

13.2.2    [***] 

except, in each case above, to the extent such Claim arose out of or resulted from or is attributable to any acts or omissions of Company or
its affiliates or Third Party sublicensees or contractors and its or their respective directors, officers, employees and agents or other circumstances for which Company has an indemnity obligation pursuant to Section 13.1 above. 

13.3    Procedure. If an Indemnified Party entitled to indemnification under Sections 13.1 or 13.2 seeks such
indemnification (wherein “Indemnified Party” in this Article 13 means a “Company Indemnified Party” and/or an “Cellscript Indemnified Party”), such Indemnified Party will: 

(i)    inform the indemnifying Party in writing of a Claim as soon as reasonably practicable after such Indemnified Party
receives notice of such Claim; 
 (ii)    permit the indemnifying Party to assume direction and control of the defense
of the Claim (including the sole right to settle such Claim at the sole discretion of the indemnifying Party, provided that (a) such settlement or compromise does not admit any fault or negligence on the part of the Indemnified Party, or
impose any obligation on, or otherwise materially adversely affect, the Indemnified Party or other Party and (b) the indemnifying Party first obtains the written consent of the Indemnified Party with respect to such settlement, which consent
will not be unreasonably withheld); 
 (iii)    cooperate as reasonably requested (at the expense of the indemnifying
Party) in the defense of the Claim; and 
 (iv)    undertake reasonable steps to mitigate any Losses with respect to the
Claim. 
 Notwithstanding anything in this Agreement to the contrary, the indemnifying Party will have no liability under Sections 13.1 or
13.2, as the case may be, for Claims settled or compromised by the Indemnified Party without the indemnifying Party’s prior written consent. 

14    INSURANCE 

14.1    Coverages. Company will procure and maintain insurance or self-insurance that covers the following minimum
liability amounts with respect to personal injury, bodily injury and property damage arising out of Company’s performance under this Agreement: (a) during the Term, comprehensive general liability, including broad form and contractual
liability, in a 

  
 26 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 
minimum amount of $[***] combined single limit per occurrence and in the aggregate; (b) prior to the commencement of clinical trials involving Licensed Products, clinical trials a minimum amount
of $[***] combined single limit per occurrence and in the aggregate; and (c) prior to the Sale of the first Licensed Product, product liability a minimum amount of $[***] combined single limit per occurrence and in the aggregate. Penn and
Cellscript may review periodically the adequacy of the minimum amounts of insurance or self-insurance for each liability coverage area required by this Section 14.1, and Penn and Cellscript reserve the right to request Company to adjust the
limits accordingly to the extent existing limits are not commercially reasonable. The required minimum amounts of insurance or self-insurance do not constitute a limitation on Company’s liability or indemnification obligations to Penn or
Cellscript under this Agreement. 
 15    ADDITIONAL PROVISIONS 

15.1    Independent Contractors. The Parties are independent contractors. Nothing contained in this Agreement is
intended to create an agency, partnership or joint venture between the Parties. At no time will either Party make commitments or incur any charges or expenses for or on behalf of the other Party. 

15.2    No Discrimination. Company will not discriminate against any employee or applicant for employment because
of race, color, sex, sexual or affectional preference, age, religion, national or ethnic origin, handicap, or veteran status. 

15.3    Compliance with Laws. Company must comply with all prevailing laws, rules and regulations that apply to its
activities or obligations under this Agreement. For example, Company will comply with applicable United States export laws and regulations. The transfer of certain technical data and commodities may require a license from the applicable agency of
the United States government and/or written assurances by Company that Company will not export data or commodities to certain foreign countries without prior approval of the agency. Penn and Cellscript do not represent that no license is required,
or that, if required, the license will issue. 
 15.4    Modification, Waiver & Remedies.
This Agreement may only be modified by a written amendment that is executed by an authorized representative of each Party. Any waiver must be express and in writing. No waiver by either Party of a breach by the other Party will constitute a waiver
of any different or succeeding breach. Unless otherwise specified, all remedies are cumulative. 

15.5    Assignment. This Agreement may not be assigned (by operation of law or otherwise) by either Party without
the prior written consent of the other Party (which consent will not be unreasonably withheld); except that, either Party may assign this Agreement without such consent to an affiliate or to a Third Party successor that purchases greater than
fifty percent (>50%) of the outstanding stock or ownership interest or all or substantially all of such Party’s business or assets to which this Agreement relates, whether by sale of shares or ownership interest, merger, consolidation, sale
of assets or otherwise, provided that, prior to said transfer, the intended assignee agrees in writing to be legally bound by this Agreement in the place and stead of the assignor and provides the
non-assigning Party with a copy of said assignee’s written undertaking. Neither Party will grant a security interest in the Sublicense or this Agreement during the Term. Any prohibited assignment or
security interest in contravention of the foregoing will be null and void. The rights and obligations of the Parties under this Agreement will be binding upon and inure to the benefit of the successors and permitted assigns of the Parties, and the
name of a Party appearing herein will be deemed to include the name of such Party’s successors and permitted assigns to the extent necessary to carry out the intent of this Section 15.5. 

  
 27 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 15.6    Notices. Any notice or other required communication (each,
a “Notice”) must be in writing, addressed to the Party’s respective Notice Address listed on the signature page, and delivered: (a) personally, with signed receipt; (b) by certified mail, postage prepaid, return
receipt requested; (c) by recognized overnight courier service, charges prepaid; or (d) by facsimile. A Notice will be deemed received: if delivered personally, on the date of delivery; if mailed, five (5) days after deposit in the
United States mail; if sent via courier, one (1) business day after deposit with the courier service; or if sent via facsimile, upon receipt of confirmation of transmission provided that a confirming copy of such Notice is sent by certified
mail, postage prepaid, return receipt requested. 
 15.7    Severability & Reformation. If
any provision of this Agreement is held to be invalid or unenforceable by a court of competent jurisdiction, then the remaining provisions of this Agreement will remain in full force and effect. Such invalid or unenforceable provision will be
automatically revised to be a valid or enforceable provision that comes as close as permitted by law to the Parties’ original intent. 

15.8    Headings & Counterparts. The headings of the articles and sections included in this
Agreement are inserted for convenience only and are not intended to affect the meaning or interpretation of this Agreement. This Agreement may be executed in one or more counterparts, each of which when executed and delivered by facsimile,
electronic transmission, or by mail delivery, will be an original and all of which shall constitute one and the same instrument. 

15.9    Governing Law. This Agreement will be governed in accordance with the laws of the Commonwealth of
Pennsylvania, without giving effect to the conflict of law provisions of any jurisdiction. 
 15.10    Dispute
Resolution. If a dispute arises between the Parties concerning any right or duty under this Agreement, then the Parties will confer, as soon as practicable, in an attempt to resolve the dispute. If the Parties are unable to resolve the dispute
amicably, then the Parties will submit to the exclusive jurisdiction of, and venue in, the state and Federal courts located in the Eastern District of Pennsylvania with respect to all disputes arising under this Agreement. Notwithstanding anything
herein to the contrary, in the event of an actual or threatened breach of this Agreement, the aggrieved Party may seek provisional equitable relief (including restraining orders, specific performance or other injunctive relief) in any court of
competent jurisdiction to protect the interests of such Party. 
 15.11    Further Assurance. Each Party shall
duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may be
necessary or as the other Party may reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes hereof, or to better assure and confirm unto such other Party its rights and remedies under this
Agreement. 
 15.12    Interpretation. Except where the context otherwise requires, wherever used, the singular
shall include the plural, the plural the singular, the use of any gender shall be applicable to all genders and the word “or” is used in the inclusive sense (and/or). The captions of this Agreement are for convenience of reference only and
in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The term “including” as used herein shall mean including, without limiting the generality of any

  
 28 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 
description preceding such term. The language of this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied against
either Party hereto. 
 15.13    Condition Precedent to Execution of this Agreement. The Parties understand and
agree that each Party’s willingness to enter into this Agreement is contingent upon the execution of both this Agreement and the mRNA RiboTherapeutics Sublicense Agreement ([***]), and, as such, the Parties’ willingness to enter into this
Agreement is conditioned upon the execution of the mRNA RiboTherapeutics Sublicense Agreement concurrently with this Agreement. 

15.14    Entire Agreement. This Agreement and the mRNA RiboTherapeutics Sublicense Agreement set forth the
complete, final and only agreements with respect to the subject matter hereof and supersede all other agreements and understandings between the Parties with respect to the subject matter hereof. The Parties acknowledge and agree that this Agreement
and the mRNA RiboTherapeutics Sublicense Agreement are separate and distinct agreements and there will be no “cross default” with respect to this Agreement and the mRNA RiboTherapeutics Sublicense Agreement. 

[Remainder of Page Intentionally Left Blank] 

  
 29 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 Each Party has caused this Agreement to be executed by its duly authorized representative. 

 

									
	CELLSCRIPT, LLC	 		 	MODERNATX, INC
					
	By:	 	/s/ Gary A. Dahl, Ph.D.	 		 	By:	 	/s/ Stephen Hoge, M.D.
	Name:	 	Gary A. Dahl, Ph.D.	 		 	Name:	 	Stephen Hoge, M.D.
	Title:	 	President	 		 	Title:	 	President

  

									
	Address:	 	CELLSCRIPT, LLC	 		 	MODERNATX, INC.
		 	726 Post Road	 		 	320 Bent Street
		 	Madison, WI 53713	 		 	Cambridge, MA 02141

 mRNA RIBOTHERAPEUTICS, INC., 

which is executing this Agreement solely 
 with respect to the
following provisions: 
  

	 	•	 	 Section 6.5.1, solely with respect to acceptance of sublicense agreements assigned by Cellscript;

  

	 	•	 	 Section 9.2, including 9.2.1 through 9.2.9; 

 

	 	•	 	 Section 9.5, including 9.5.1 through 9.5.8; and 

 

	 	•	 	 Article 10. 

  

			
	By:	 	/s/ Gary A. Dahl, Ph.D.
	Name:	 	Gary A. Dahl, Ph.D.
	Title:	 	President

  
 30 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 EXHIBIT INDEX 

 

			
		
	Exhibit A	  	Patents and Patent Applications in Patent Rights
		
	Exhibit B	  	Sublicense Disclosure Report
		
	Exhibit C	  	Form of Royalty Report
		
	Exhibit D	  	Cellscript’s Exhibit D Patents

  
 31 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 EXHIBIT A – Patents and Patent Applications in Patent Rights 

EXHIBIT A-1 [***] 
  

									
	 Patent

Application No.
	  	 Patent No.
	  	 Filing Date
	  	 Issue Date
	  	 Title

	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  		  	[***]	  		  	[***]
	[***]	  		  	[***]	  		  	[***]
	[***]	  		  	[***]	  		  	[***]
	[***]	  		  	[***]	  		  	[***]

  
 32 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 EXHIBIT A – Patents and Patent Applications in Patent Rights 

(continued) 
 EXHIBIT A-2 [***] 
  

									
	 Patent

Application No.
	  	 Patent No.
	  	 Filing Date
	  	 Issue Date
	  	 Title

	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  		  	[***]	  		  	[***]
	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  		  	[***]	  		  	[***]
	[***]	  		  	[***]	  		  	[***]
	[***]	  		  	[***]	  		  	[***]
	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]
	[***]	  		  	[***]	  		  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  		  	[***]	  		  	[***]

  
 33 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 Exhibit B 

Sublicense Disclosure Report 

[***] 

  
 34 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 EXHIBIT C – Format of Royalty Report 

[***] 

  
 35 

  

 [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED 

MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE 

COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES 

ACT OF 1933, AS AMENDED 
  

 Exhibit D 

Exhibit D Patents Sublicensed to Company under Section 1.7. 

 

									
	 Patent Application No.
	  	 Patent No.
	  	 Filing Date
	  	 Issue Date
	  	 Title

	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]	  		  	[***]

  
 36EX-10.11

 Exhibit 10.11 

MODERNA THERAPEUTICS, INC. 

EXECUTIVE SEVERANCE PLAN 

1.    Purpose. Moderna Therapeutics, Inc. (the “Company”) considers it essential to the best interests of
the Company to foster the continuous employment of key management personnel. The Board of Directors of the Company (the “Board”) recognizes, however, that, as is the case with many corporations, the possibility of an involuntary
termination of employment, either before or after a Change in Control (as defined in Section 2 hereof), exists and that such possibility, and the uncertainty and questions that it may raise among management, may result in the departure or
distraction of management personnel to the detriment of the Company. Therefore, the Board has determined that the Moderna Therapeutics, Inc. Executive Severance Plan (the “Plan”) should be adopted to reinforce and encourage the continued
attention and dedication of the Company’s Covered Executives (as defined in Section 2 hereof) to their assigned duties without distraction. Nothing in this Plan shall be construed as creating an express or implied contract of
employment and nothing shall alter the “at will” nature of the Covered Executives’ employment with the Company. 

2.    Definitions. The following terms shall be defined as set forth below: 

(a)    “Accounting Firm” shall mean a nationally recognized accounting firm selected
by the Company. 
 (b)    “Administrator” means the Board or the Compensation Committee of the Board.

 (c)    “Cause” shall mean, and shall be limited to, the occurrence of any one or more of the
following events: 
 (i)    the Covered Executive’s unauthorized use or disclosure of the
Company’s confidential information or trade secrets; 
 (ii)    the Covered Executive’s
material breach of any agreement between the Covered Executive and the Company; 
 (iii)    the Covered
Executive’s material failure to comply with the Company’s written policies or rules; 

(iv)    the Covered Executive’s gross negligence or willful misconduct in connection with the
Executive’s performance of his/her duties to the Company; 
 (v)    the Covered Executive’s
continuing failure to perform assigned duties after receiving written notification of the failure from the Company and, if curable, a period of thirty (30) days to cure such failure; or 

(vi)    the Covered Executive’s failure to cooperate in good faith with a governmental or internal
investigation of the Company or its directors, officers or employees, if the Company has requested the Covered Executive’s cooperation. 

  
 1 

 (d)    “Change in Control” shall mean 

(i)    the sale of all or substantially all of the assets of the Company on a consolidated basis to an
unrelated person or entity; 
 (ii)    a merger, reorganization or consolidation pursuant to which the
holders of the Company’s outstanding voting power and outstanding stock immediately prior to such transaction do not own a majority of the outstanding voting power and outstanding stock or other equity interests of the resulting or successor
entity (or its ultimate parent, if applicable) immediately upon completion of such transaction; 

(iii)    the sale of all of the outstanding stock of the Company to an unrelated person, entity or group
thereof acting in concert; or 
 (iv)    any other transaction in which the owners of the Company’s
outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the Company or any successor entity immediately upon completion of the transaction other than as a result of the
acquisition of securities directly from the Company. 
 (e)    “Change in Control Period” shall mean the
period beginning on the date of a Change in Control and ending on the one-year anniversary of the Change in Control. 

(f)    “Code” shall mean the Internal Revenue Code of 1986, as amended. 

(g)    “Covered Executives” shall mean the individuals designated as such by the Administrator and who are
listed in Exhibit A, attached hereto, as such exhibit is amended by the Administrator from time to time. 

(h)    “Date of Termination” shall mean the date that a Covered Executive’s employment with the
Company (or any successor) ends, which date shall be specified in the Notice of Termination. Notwithstanding the foregoing, a Covered Executive’s employment shall not be deemed to have been terminated solely as a result of the Covered Executive
becoming an employee of any direct or indirect successor to the business or assets of the Company. 

(i)    “Disability” shall mean the following: if through any illness, injury, accident or condition of
either a physical or psychological nature, the Covered Executive becomes unable to perform substantially all of his duties and responsibilities for a continuous period of sixteen (16) consecutive weeks or for any
twenty-six (26) weeks within a fifty-two (52) week period. Determinations as to whether Covered Executive
is Disabled shall be made by a physician selected by the Board or its insurers and acceptable to the Covered Executive or the Covered Executive’s legal representative, such agreement as to acceptability not to be unreasonably withheld or
delayed. 
 (j)    “Good Reason” shall mean that the Covered Executive has complied with the “Good
Reason Process” following the occurrence of any of the following events: 

  
 2 

 (i)    a material diminution in the Covered
Executive’s annual base salary other than across the board decreases in annual base salary similarly affecting all executives of the Company; 

(ii)    the Company requiring the Covered Executive to relocate (other than for travel incident to the
Covered Executive’s performance of his or her duties on behalf of the Company) a distance of more than fifty (50) miles from the Covered Executive’s current principal place of business; or 

(iii)    any material diminution in the Covered Executive’s position, responsibilities, authority or
duties. 
 For purposes of Section 2(j)(iii), a change in the reporting relationship, or a change in a title will not, by itself, be sufficient to
constitute a material diminution of responsibilities, authority or duty. 
 (k)    “Good Reason Process”
shall mean: 
 (i)    the Covered Executive reasonably determines in good faith that a “Good
Reason” condition has occurred; 
 (ii)    the Covered Executive notifies the Company in writing of
the first occurrence of the Good Reason condition within sixty (60) days of the first occurrence of such condition; 

(iii)    the Covered Executive cooperates in good faith with the Company’s efforts, for a period of
not less than thirty (30) days following such notice (the “Cure Period”), to remedy the condition; 

(iv)    notwithstanding such efforts, the Good Reason condition continues to exist following the Cure
Period; and 
 (v)    the Covered Executive terminates his or her employment and provides the Company
with a Notice of Termination with respect to such termination, each within sixty (60) days after the end of the Cure Period. 
 If the
Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred. 

(l)    “Notice of Termination” shall mean a written notice which shall indicate the specific termination
provision in this Plan relied upon for the termination of a Covered Executive’s employment and the Date of Termination. 

(m)    “Participation Agreement” shall mean an agreement between a Covered Executive
and the Company that acknowledges the Covered Executive’s participation in the Plan.  

  
 3 

 (n)    “Qualified Termination Event” shall mean
(i) a termination of the Covered Executive’s employment by the Company other than for Cause, death or Disability or (ii) the Covered Executive’s resignation from the Company for Good Reason. 

(o)    “Restrictive Covenants Agreement” shall mean the Employee Confidentiality, Non-Competition, Non-Solicitation and Inventions Assignment Agreement or similar agreement entered into between the Covered Executive and the Company. 

3.    Administration of the Plan. 

(a)    Administrator. The Plan shall be administered by the Administrator. 

(b)    Powers of Administrator. The Administrator shall have all powers necessary to enable it properly to carry out
its duties with respect to the complete control of the administration of the Plan. Not in limitation, but in amplification of the foregoing, the Administrator shall have the power and authority in its discretion to: 

(i)    construe the Plan to determine all questions that shall arise as to interpretations of the
Plan’s provisions; 
 (ii)    determine which individuals are and are not Covered Executives,
determine the benefits to which any Covered Executives may be entitled, the eligibility requirements for participation in the Plan and all other matters pertaining to the Plan; 

(iii)    adopt amendments to the Plan which are deemed necessary or desirable to comply with all
applicable laws and regulations, including but not limited to Code Section 409A and the guidance thereunder; 

(iv)    make all determinations it deems advisable for the administration of the Plan, including the
authority and ability to delegate administrative functions to a third party; 
 (v)    decide all
disputes arising in connection with the Plan; and 
 (vi)    otherwise supervise the administration of
the Plan. 
 (c)    All decisions and interpretations of the Administrator shall be binding on all persons, including the
Company and Covered Executives. 
 4.    Eligibility. All Covered Executives who have executed and submitted to
the Company a Participation Agreement, and satisfied such other requirements as may be determined by the Administrator, are eligible to participate in the Plan. 

5.    Termination Benefits Generally. In the event a Covered Executive’s employment with the Company is
terminated for any reason, the Company shall pay or provide to the Covered Executive any earned but unpaid salary, unpaid expense reimbursements in accordance with Company policy, accrued but unused vacation, if any and any vested benefits the
Covered Executive may have under any employee benefit plan of the Company in accordance with the 

  
 4 

 
terms and conditions of such employee benefit plan (collectively, the “Accrued Benefits”), within the time required by law but in no event more than sixty (60) days after the Date
of Termination. 
 6.    Termination Not in Connection with a Change in Control. In the event a Qualified
Termination occurs at any time other than during the Change in Control Period, with respect to such Covered Executive, in addition to the Accrued Benefits, subject to his or her execution of a separation agreement in a form and manner satisfactory
to the Company containing, among other provisions, a general release of claims in favor of the Company and related persons and entities, confidentiality, return of property, non-disparagement and reaffirmation
of the Restrictive Covenants Agreement (the “Separation Agreement and Release”) and the Separation Agreement and Release becoming irrevocable, all within the time period set forth in the Separation Agreement and Release but in no event
more than sixty (60) days after the Date of Termination, and subject to the Covered Executive complying with the Separation Agreement and Release, the Company shall: 

(a)    pay the Covered Executive an amount equal to the sum of (i) twelve (12) months of the Covered Executive’s
annual base salary in effect immediately prior to the Qualified Termination Event plus (ii) an amount equal to the Covered Executive’s annual target bonus in effect immediately prior to the Qualified Termination Event multiplied by a
fraction with a numerator equal to the number of full weeks elapsed in the then current fiscal year prior to the Date of Termination and with a denominator equal to fifty-two (52); and 

(b)    if the Covered Executive was participating in the Company’s group health plan immediately prior to the Date of
Termination and elects COBRA health continuation, then the Company shall pay to the Covered Executive a monthly cash payment for twelve (12) months or the Covered Executive’s COBRA health continuation period, whichever ends earlier, in an
amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the Covered Executive if the Covered Executive had remained employed by the Company, based on the premiums as of the Date of
Termination. 
 The amounts payable under Section 6(a) and (b) shall be paid out in substantially equal installments in accordance with the
Company’s payroll practice over twelve (12) months commencing within sixty (60) days after the Date of Termination; provided, however, that if the 60-day period begins in one
(1) calendar year and ends in a second calendar year, the severance shall begin to be paid in the second calendar year by the last day of such 60-day period; provided further, that the initial payment
shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this Plan is intended to constitute a separate payment for
purposes of Treasury Regulation Section 1.409A-2(b)(2). 

7.    Termination in Connection with a Change in Control. In the event the Qualified Termination Event occurs
within the Change in Control Period, then with respect to such Covered Executive, in addition to the Accrued Benefits, subject to his or her execution and non-revocation of the Separation Agreement and
Release, all within the time period set forth in the Separation Agreement and Release, but in no event more than sixty (60) days after the Date of Termination, the Company shall: 

  
 5 

 (a)    cause 100% of the outstanding and unvested equity awards with
time-based vesting held by the Covered Executive to immediately become fully exercisable or nonforfeitable as of the Date of Termination. Notwithstanding the foregoing, in the event of a Change in
Control where the parties to such Change in Control do not provide for the assumption, continuation or substitution of equity awards of the Company, any and all outstanding and unvested equity awards held by the Covered Executive shall be subject to
Section 3(d) of the Company’s 2018 Stock Option and Incentive Plan, if adopted by the Board. 
 (b)    pay to
the Covered Executive an amount equal to the sum of (i) 150% of the Covered Executive’s annual base salary in effect immediately prior to the Qualified Termination Event (or the Covered Executive’s annual base salary in effect immediately
prior to the Change in Control, if higher) plus (ii) 150% of the Covered Executive’s annual target bonus in effect immediately prior to the Qualified Termination Event (or the Covered Executive’s target bonus in effect immediately prior to
the Change in Control, if higher, (such higher annual target bonus, the “Applicable Bonus”)) plus (iii) an amount equal to the Covered Executive’s Applicable Bonus multiplied by a fraction with a numerator equal to the number of
full weeks elapsed in the then current fiscal year prior to the Date of Termination and with a denominator equal to fifty-two (52); and 

(c)    if the Covered Executive was participating in the Company’s group health plan immediately prior to the Date of
Termination and elects COBRA health continuation, then the Company shall pay to the Covered Executive a lump sum cash payment in an amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the
Covered Executive if the Covered Executive had remained employed by the Company for eighteen (18) months after the Date of Termination, based on the premiums as of the Date of Termination. 

The amounts payable under Section 7(b) and (c), as applicable, shall be paid out in a lump sum within sixty (60) days after the Date of Termination;
provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the amounts shall be paid in the second calendar year no later than the last day of the 60-day period. For the avoidance of doubt, the severance pay and benefits provided in this Section 7 shall apply in lieu of, and expressly supersede, the provisions of Section 6 and no Covered Executive
shall be entitled to the severance pay and benefits under both Section 6 and 7 hereof. 
 8.    Additional
Limitation. 
 (a)    Anything in this Plan to the contrary notwithstanding, in the event that the amount of any
compensation, payment or distribution by the Company to or for the benefit of the Covered Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Plan or otherwise, calculated in a manner consistent with
Section 280G of the Code and the applicable regulations thereunder (the “Aggregate Payments”), would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate Payments shall be reduced (but not below
zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which the Covered Executive becomes subject to the excise tax imposed by Section 4999 of the Code; provided that such reduction shall only occur if it
would result in the Covered Executive receiving a higher After Tax Amount (as defined below) than the Covered Executive 

  
 6 

 
would receive if the Aggregate Payments were not subject to such reduction. In the event of such reduction, the Aggregate Payments shall be reduced in the following order, in each case, in
reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section 280G of the Code: (1) cash payments not subject to Section 409A
of the Code; (2) cash payments subject to Section 409A of the Code; (3) equity-based payments and acceleration; and (4) non-cash forms of benefits; provided that in the case of all the
foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. §1.280G-1, Q&A-24(b) or (c) shall be
reduced before any amounts that are subject to calculation under Treas. Reg. §1.280G-1, Q&A-24(b) or (c). 

(b)    For purposes of this Section 8, the “After Tax Amount” means the amount of the Aggregate Payments
less all federal, state, and local income, excise and employment taxes imposed on the Executive as a result of the Executive’s receipt of the Aggregate Payments. For purposes of determining the After Tax Amount, the Executive shall be deemed to
pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual
taxation in each applicable state and locality, net of the maximum reduction in federal income taxes (if any) which could be obtained from deduction of such state and local taxes. 

(c)    The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to Section 8(a)
shall be made by the Accounting Firm, which shall provide detailed supporting calculations both to the Company and the Covered Executive within fifteen (15) business days of the Date of Termination, if applicable, or at such earlier time as is
reasonably requested by the Company or the Covered Executive. Any determination by the Accounting Firm shall be binding upon the Company and the Covered Executive. 

9.    Employee Non-Competition,
Non-Solicitation and Confidentiality and Assignment Agreement. 

(a)    Employee Non-Competition,
Non-Solicitation and Confidentiality and Assignment Agreement. As a condition to participating in the Plan, each Covered Executive shall continue to comply with the terms and conditions contained in the
Restrictive Covenants Agreements or similar agreement entered into between the Covered Executive and the Company and such other agreement(s) as designated in the applicable Participation Agreement. If a Covered Executive has not entered into a
Restrictive Covenants Agreement or similar agreement with the Company, he or she shall enter into such agreement prior to participating in the Plan.  

10.    Withholding. All payments made by the Company under this Plan shall be subject to any tax or other amounts
required to be withheld by the Company under applicable law. 
 11.    Section 409A. 

(a)    Anything in this Plan to the contrary notwithstanding, if at the time of the Covered Executive’s
“separation from service” within the meaning of Section 409A of the Code, 

  
 7 

 
the Company determines that the Covered Executive is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit
that the Covered Executive becomes entitled to under this Plan would be considered deferred compensation subject to the twenty (20) percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of
Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (i) six (6) months and one (1) day after the Covered Executive’s separation from
service, or (ii) the Covered Executive’s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that
would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule. 

(b)    The parties intend that this Plan will be administered in accordance with Section 409A of the Code and that all
amounts payable hereunder shall be exempt from the requirements of such section as a result of being “short term deferrals” for purposes of Section 409A of the Code to the greatest extent possible. To the extent that any provision of
this Plan is not exempt from Section 409A of the Code and ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner to comply with Section 409A of the Code. Each payment pursuant to
this Plan is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The parties agree that this Plan may be amended, as reasonably requested by either party,
and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party. 

(c)    To the extent that any payment or benefit described in this Plan constitutes
“non-qualified deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Covered Executive’s termination of employment, then
such payments or benefits shall be payable only upon the Covered Executive’s “separation from service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set
forth in Treasury Regulation Section 1.409A-1(h). 
 (d)    All in-kind benefits provided and expenses eligible for reimbursement under this Plan shall be provided by the Company or incurred by the Covered Executive during the time periods set forth in this Plan. All
reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement
in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for
another benefit. 
 (e)    The Company makes no representation or warranty and shall have no liability to the Covered
Executive or any other person if any provisions of this Plan are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section. 

  
 8 

 12.    Notice and Date of Termination. 

(a)    Notice of Termination. A termination of the Covered Executive’s employment shall be communicated by
Notice of Termination from the Company to the Covered Executive or vice versa in accordance with this Section 12. 

(b)    Notice to the Company. Any notices, requests, demands, and other communications provided for by this Plan
shall be sufficient if in writing and delivered in person or sent by registered or certified mail, postage prepaid, to a Covered Executive at the last address the Covered Executive has filed in writing with the Company, or to the Company at the
following physical or email address: 
 Moderna Therapeutics, Inc. 

Attention: Chief Human Resources Officer 

200 Technology Square 

Cambridge, MA 02139 

Annie.drapeau@modernatx.com 

13.    No Mitigation. The Covered Executive is not required to seek other employment or to attempt in any way to
reduce any amounts payable to the Covered Executive by the Company under this Plan. 
 14.    Benefits and
Burdens. This Plan shall inure to the benefit of and be binding upon the Company and the Covered Executives, their respective successors, executors, administrators, heirs and permitted assigns. In the event of a Covered Executive’s death
after a termination of employment but prior to the completion by the Company of all payments due to him or her under this Plan, the Company shall continue such payments to the Covered Executive’s beneficiary designated in writing to the Company
prior to his or her death (or to his or her estate, if the Covered Executive fails to make such designation). 

15.    Enforceability. If any portion or provision of this Plan shall to any extent be declared illegal or
unenforceable by a court of competent jurisdiction, then the remainder of this Plan, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected
thereby, and each portion and provision of this Plan shall be valid and enforceable to the fullest extent permitted by law. 

16.    Waiver. No waiver of any provision hereof shall be effective unless made in writing and signed by the
waiving party. The failure of any party to require the performance of any term or obligation of this Plan, or the waiver by any party of any breach of this Plan, shall not prevent any subsequent enforcement of such term or obligation or be deemed a
waiver of any subsequent breach. 
 17.    Non-Duplication of Benefits and Effect on Other Plans. Notwithstanding
any other provision in the Plan to the contrary, the benefits provided hereunder shall be in lieu of any other severance payments and/or benefits provided by the Company, including any such 

  
 9 

 
payments and/or benefits pursuant to an employment agreement or offer letter between the Company and the Covered Executive, other than as provided in Section 3(d) of the Company’s 2018
Stock Option and Incentive Plan, if adopted by the Board. 
 18.    No Contract of Employment. Nothing in this
Plan shall be construed as giving any Covered Executive any right to be retained in the employ of the Company or shall affect the terms and conditions of a Covered Executive’s employment with the Company. 

19.    Amendment or Termination of Plan. The Company may amend or terminate this Plan at any time or from time to
time, but no such action shall adversely affect the rights of any Covered Executive without the Covered Executive’s written consent. 

20.    Governing Law. This Plan shall be construed under and be governed in all respects by the laws of the
Commonwealth of Massachusetts, without giving effect to the conflict of laws principles. 
 21.    Obligations of
Successors. In addition to any obligations imposed by law upon any successor to the Company, any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the
Company shall expressly assume and agree to perform this Plan in the same manner and to the same extent that the Company would be required to perform if no such succession had taken place. 

22.    Effectiveness and Term. This Plan shall be effective as of June 13, 2018. 

 [DATE] 

[NAME] 
 [ADDRESS] 

[ADDRESS] 
  

	Re:	 Executive Severance Plan 

Dear [NAME], 
 Moderna Therapeutics, Inc. (the
“Company”) is pleased to inform you that you have been designated as an eligible participant in the Company’s Executive Severance Plan, as amended from time to time (the “Severance Plan”), a copy of which (excluding the
exhibits thereto) is attached hereto as Exhibit A. You have been designated as a Covered Executive under the Severance Plan. 
 Under certain
circumstances, you will be eligible for certain severance benefits as described in the Severance Plan. Any and all such severance benefits are subject to the terms and conditions of the Severance Plan. 

As a condition to participate in the Severance Plan, you hereby acknowledge that the severance benefits that may be provided to you under the Severance Plan
will supersede and replace any severance benefit plan, policy or practice previously maintained by the Company or any of its affiliates that may have been applicable to you and any severance benefits under any individually negotiated employment
agreement, offer letter agreement or equity award agreement between you and the Company or any of its affiliates, as may be amended from time to time, including without limitation the [offer letter][equity award agreement] between you and Moderna
Therapeutics, Inc., dated [DATE], but other than Section 3(d) of the Company’s 2018 Stock Option and Incentive Plan, if adopted by the Company’s board of directors. In addition, as a condition to participate in the Severance Plan, you
hereby acknowledge that you will continue to comply with the Employee Confidentiality, Non-Competition, Non-Solicitation and Inventions Assignment Agreement entered into
between you and the Company on [DATE].
 Please review the information in this letter and the Severance Plan carefully. If you have any questions regarding
the letter or the Severance Plan, please contact Annie Drapeau at Annie.drapeau@modernatx.com. 
 To accept the terms of this letter and participate in the
Severance Plan, please sign and date this letter in the space provided below and return the signed copy to Annie Drapeau by [DATE] (the “Expiration Date”). If you do not return the signed copy by the Expiration Date, the terms of this
letter shall be null and void and you may not participate in the Severance Plan. 
  

	
	Moderna Therapeutics, Inc.
	
	   

	Name:
	Title:

  

	
	Agreed and Accepted:
	
	   

	Name:
	Date:

  

  
 Signature Page to
Participation Letter 

 Exhibit A 

Moderna Therapeutics, Inc. Executive Severance Plan

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00289-of-00352.parquet"}]]